Original Report

First example of an FY*01 allele associated with weakened expression of Fya on red blood cells
P.A. Arndt, T. Horn, J.A. Keller, R. Young, S.M. Heri, and M.A. Keller

Original Report

Clinical and reference lab characteristics of patients with suspected direct antiglobulin test (DAT)-negative immune hemolytic anemia
M.S. Karafin, G.A. Denomme, M. Schanen, and J.L. Gottschall

Case Report

Blocked D phenomenon and relevance of maternal serologic testing
A. Jain, V. Kumawat, and N. Marwaha

Case Report

Anti-Jk3 in a Filipino man
S. McCaskill, S. Wise, and S. Tinsley

Case Report

Severe hemolytic disease of the fetus and newborn due to anti-C+G

Letter to the Editor

CD177/NB1 receptor expression is dynamically regulated in sepsis patients
A. Schreiber, A. Jennerjahn, and R. Kettritz

Letter to the Editor

Alternative to providing ABO-incompatible donors for patients in end-stage renal disease: renal transplant registries, the need of the hour
S. Malhotra, G. Sagar, H.K. Dhawan, and R.R. Sharma

Announcements

Advertisements

Instructions for Authors

Subscription Information
Immunohematology is published quarterly (March, June, September, and December) by the American Red Cross, National Headquarters, Washington, DC 20006.

Immunohematology is indexed and included in Index Medicus and MEDLINE on the MEDLARS system. The contents are also cited in the EBASE/Excerpta Medica and Elsevier BIOBASE/Current Awareness in Biological Sciences (CABS) databases.

The subscription price is $50 for individual, $100 for institution (U.S.), and $60 for individual, $100 for institution (foreign), per year.

Subscriptions, Change of Address, and Extra Copies:
Immunohematology, P.O. Box 40325
Philadelphia, PA 19106
Or call (215) 451-4902

Web site: www.redcross.org/about-us/publications/immunohematology
Copyright 2015 by The American National Red Cross
ISSN 0894-203X

On Our Cover

An artist of humble origins and a champion of Naturalism in 19th Century France, Jules Bastien-Lepage often portrayed peasants and the poor in a sympathetic though unromantic light. His Joan of Arc, painted in 1879, more than 40 years before her canonization, depicts a flesh and blood girl with a real farmhouse and tipped over spinning wheel behind her, in contrast to the three phantasmal saints floating in the trees who guide her. While she wears no armor, and there is more wonder than fire in her eyes, she would lead French defenders in battle after battle against invading English forces. Schreiber’s letter in this issue concerns CD177 expression in neutrophils, critical in the body’s protection against infection.

David Moolten, MD
First example of an FY*01 allele associated with weakened expression of Fya on red blood cells

P.A. Arndt, T. Horn, J.A. Keller, R. Young, S.M. Heri, and M.A. Keller

Duffy antigens are important in immunohematology. The reference allele for the Duffy gene (FY) is FY*02, which encodes Fyb. An A>G single nucleotide polymorphism (SNP) at coding nucleotide (c.) 125 in exon 2 defines the FY*01 allele, which encodes the antithetical Fya. A C>T SNP at c.265 in the FY*02 allele is associated with weakening of Fyb expression on red blood cells (RBCs) (called FyX). Until recently, this latter change had not been described on a FY*01 background allele. Phenotype-matched units were desired for a multi-transfused Vietnamese fetus with α-thalassemia. Genotyping of the fetus using a microarray assay that interrogates three SNPs (c.1-67, c.125, and c.265) in FY yielded indeterminate results for the predicted Duffy phenotype. Genomic sequencing of FY exon 2 showed that the fetal sample had one wild-type FY*01 allele and one new FY*01 allele with the c.265C>T SNP, which until recently had only been found on the FY*02 allele. Genotyping performed on samples from the proband’s parents indicated that the father had the same FY genotype as the fetus. Flow cytometry, which has been previously demonstrated as a useful method to study antigen strength on cells, was used to determine if this new FY*01 allele was associated with reduced Fya expression on the father’s RBCs. Median fluorescence intensity of the father’s RBCs (after incubation with anti-Fya and fluorescein-labeled anti-IgG) was similar to known FY*01 heterozygotes and significantly weaker than known FY*01 homozygotes. In conclusion, the fetus and father both had one normal FY*01 allele and one new FY*01 allele carrying c.265C>T. This new FY*01 allele, named FY*01W.01, is associated with weakened expression of Fya on RBCs. Immunohematology 2015;31:103–107.

Key Words: Duffy, Fya, flow cytometry, genotyping, blood group antigen

The Duffy blood group antigens, expressed on the Duffy antigen receptor for chemokines (DARC), are important, not only in the field of immunohematology where Duffy antibodies can cause transfusion reactions and hemolytic disease of the fetus and newborn, but also in the fields of anthropology, genetics, and disease, where the DARC protein is the receptor for the malarial parasite Plasmodium vivax. The Duffy gene (FY) consists of two exons on chromosome 1. The reference allele FY*02 (FY*B) encodes for Fyb, Fy3, Fy5, and Fy6. An A>G single nucleotide polymorphism (SNP) at coding nucleotide (c.) 125 in exon 2 defines the FY*01 (FY*A) allele and results in an asparagine to glycine amino acid substitution in the protein (p.42 Asp>Gly) that results in expression of Fya on red blood cells (RBCs) (Table 1). There are several different mutations leading to the FY*01 phenotype [Fya(a–b–), Fya:–3]. The most common is the FY*02N.01 allele; a t>c SNP at c.–67 located in a transcription factor binding site called a GATA box hinders binding of the transcription factor GATA-1, which results in loss of FY*02 expression on RBCs but not in tissues. Another prevalent Duffy variant is the C>T mutation at c.265 on the FY*02 allele, encoding a p.89 Arg to Cys amino acid substitution that causes weakening of FyX, Fy3, and Fy6 expression (FyX). The microarray assay, HEA BeadChip™ (BioArray Solutions, Immucor, Norcross, GA), tests for these three notable SNPs to predict the FY phenotype: Fy*/FyX (c.125G/A), GATA (c.–67t/c), and FyX (c.265C/T). A GATA box mutation has been described on the FY*01 allele that results in the Fya(a–b–) phenotype, but the c.265C>T (FyX) change had not been described on the FY*01 allele until recently.

Flow cytometry has been shown to be a useful method for detecting differences in antigen strength (e.g., attributable to zygosity) and has been used to study the expression of

<table>
<thead>
<tr>
<th>Allele</th>
<th>Fy nucleotides</th>
<th>Promoter Exon 2</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY<em>02 (FY</em>B)</td>
<td>t A C G</td>
<td>Reference allele; Fya</td>
<td></td>
</tr>
<tr>
<td>FY*02N.01</td>
<td>c A C G</td>
<td>Fya(a–b–) erythroid cells only</td>
<td></td>
</tr>
<tr>
<td>FY*02W.01</td>
<td>t A T A</td>
<td>Fya(b+*), Fya</td>
<td></td>
</tr>
<tr>
<td>FY*02W.02</td>
<td>t A T A</td>
<td>c.145G&gt;T; Fya(b+*), Fya</td>
<td></td>
</tr>
<tr>
<td>FY*02W.03</td>
<td>t A C G</td>
<td>c.266G&gt;A; Fya(b+*)</td>
<td></td>
</tr>
<tr>
<td>FY*02W.04</td>
<td>t A C G</td>
<td>c.901C&gt;T; Fya(b+*)</td>
<td></td>
</tr>
<tr>
<td>FY<em>01 (FY</em>A)</td>
<td>t G C G</td>
<td>Fya</td>
<td></td>
</tr>
<tr>
<td>FY*01W.01</td>
<td>t G T G</td>
<td>Fya(a+)</td>
<td></td>
</tr>
<tr>
<td>FY*01W.02</td>
<td>t G T A</td>
<td>Fya(a+*), Fya</td>
<td></td>
</tr>
</tbody>
</table>

The allele in bold (FY*01W.01) is described in the text.
Duffy antigens on RBCs of different phenotypes or of different ages.\textsuperscript{8,10,12,13–20} We describe the first reported example of an FY\textsuperscript{*}01 allele with the c.265C>T (FyX) change; this allele was shown to be associated with weak expression of Fy\textsuperscript{a} as determined by flow cytometry.\textsuperscript{6}

**Case Report**

The patient was a Vietnamese male fetus with \(\alpha\)-thalassemia. A decision was made to provide the fetus with phenotype-matched RBC units but, because of multiple recent intrauterine transfusions, a genotype was needed to determine the fetus’ predicted phenotype. Molecular typing results (HEA BeadChip, Immucor) indicated the following phenotype: C+ c– E– e+; K– k+ Kp(a–b+) Js(a–b+) Jk(a+b+); M– N+ S– s+; Lu(a–b+); Di(a–b+); Co(a+b–); Do(a+b+).Jo(a+) Hy+; LW(a+b–); SC:1,–2, but the Fy\textsuperscript{a} and Fy\textsuperscript{b} results were “indeterminate.” Further molecular studies were performed on the fetal DNA to determine the Fy phenotype. Blood samples were obtained from both the mother and father for molecular and serologic testing.

**Materials and Methods**

**Serologic Testing**

RBCs from the proband’s parents were typed with three different sources of anti-Fy\textsuperscript{a} and anti-Fy\textsuperscript{b} (Immucor; Ortho Clinical Diagnostics, Raritan, NJ; American Red Cross, Washington, DC) by the indirect antiglobulin test (IAT). The grading scale included ½+ increments.\textsuperscript{21}

**Molecular Testing**

Genomic DNA was isolated from mononuclear cells using a kit (QIAamp DNA Blood Mini Kit, Qiagen, Valencia, CA). Microarray testing was performed (HEA BeadChip, Immucor) with software (BASIS 3.3, BioArray Solutions Ltd., Warren, NJ). Amplification and Sanger sequencing of FY exon 2 was performed (BigDye Terminator Kit, Life Technologies, Grand Island, NY), and the resulting sequence was aligned to the consensus sequence (Sequencher 5.0, GeneCodes Corp., Ann Arbor, MI). Polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) using BanI was used to interrogate FY\textsuperscript{*}01/FY\textsuperscript{*}02 (c.125G>A) as described by Tournamille et al.\textsuperscript{22}

**Flow Cytometry**

A previously described flow cytometric method\textsuperscript{23} was used to study the strength of Fy\textsuperscript{a} on the proband’s parents’ RBCs; known genotyped and/or phenotyped donor or reagent RBCs were tested in parallel as controls. Briefly, 0.1 mL 5% washed RBCs were incubated with 0.2 mL undiluted polyclonal anti-Fy\textsuperscript{a} (Immucor) for 30 minutes at 37°C, washed four times with 0.85% (w/v) phosphate-buffered saline (PBS), then incubated with a dilution of a tagged antihuman globulin (FITC Fab anti-IgG, MP Biomedicals, Aurora, OH) for 30 minutes at room temperature, and washed once with 0.2% bovine serum albumin in PBS. Ten thousand events per sample were acquired by a flow cytometer (FACSort, BD Biosciences, San Jose, CA) using logarithmic amplification of forward scatter, side scatter, and green fluorescence. A gate was set on the forward versus side scatter dot plot to exclude debris, and the median green fluorescence of the gated events was obtained using software (CellQuest Pro, BD Biosciences). In addition to testing by flow cytometry, the RBCs incubated with anti-Fy\textsuperscript{a} were also tested by IAT (Anti-IgG, Ortho Clinical Diagnostics).

**Results**

**Serologic Testing**

The mother’s RBCs and the father’s RBCs both typed as Fy(a+b–); both reacted 4+ with all three sources of anti-Fy\textsuperscript{a}.

**Molecular Testing**

The molecular testing yielded an indeterminate predicted phenotype for the Duffy antigens on the proband’s sample. The microarray assay (HEA BeadChip, Immucor) results showed the fetal sample to be homozygous for c.125G, associated with the FY\textsuperscript{*}01 (FY\textsuperscript{A}) phenotype, and heterozygous for c.265C>T change associated with the FY\textsuperscript{*}02W.01 and FY\textsuperscript{*}02W.02 alleles, while being homozygous for c.1-67t. Genomic sequencing of FY exon 2 confirmed the genotype results and determined that the c.298G>A SNP associated with the known FY\textsuperscript{*}02W.01 and FY\textsuperscript{*}02W.02 alleles was not present. The mother’s predicted phenotype by molecular typing was Fy(a+b–), and the sample was negative for the c.265C>T variant. The father’s sample, like that of the fetus, yielded indeterminate calls for Duffy antigens on the microarray assay. PCR-RFLP analysis showed the father’s sample to be homozygous for c.125G and heterozygous for c.265C/T, concordant with the molecular findings.

**Flow Cytometry**

Flow cytometry (median fluorescence) results of the controls [5 Fy(a+b–) donors who genotyped as homozygous for FY\textsuperscript{*}01, 5 Fy(a+b+) donors who were obligate heterozygotes for FY\textsuperscript{*}01, 3 Fy(a+b–) donors who genotyped as FY\textsuperscript{*}01/ FY\textsuperscript{*}02N.01 and thus were heterozygous for FY\textsuperscript{*}01, and 2
Fy(a–b+) donors] and the two Fy(a+b–) parents of the fetus are shown in Figure 1. The median fluorescence results of the donors who were homozygous for Fy*01 were clearly stronger than the median fluorescence results from the donors who were heterozygous, and two distinct groups were apparent. The father’s sample, with only one normal Fy*01 allele, gave results that fell clearly in the heterozygous group indicating that his other allele, the new Fy*01 allele, coded for a weakened expression of Fy+. The median fluorescence results of the mother’s sample fell in the gap between the homozygotes and the heterozygotes and could not be clearly distinguished as belonging to either group. The IAT results of all the Fy(a+) controls and the parents’ RBCs after incubation with anti-Fy+ were similar (3–3½+).

![Fig. 1. Median fluorescence (MF) results of RBCs from (1) five Fy*01 homozygotes [phenotype = Fy(a+b–), genotype = Fy*01/ Fy*01, MF = 70–98], (2) two groups of Fy*01 heterozygotes [phenotype = Fy(a+b+), genotype not determined (n = 5; MF = 40–58), and phenotype = Fy(a+b–), genotype = Fy*01/Fy*02N.01 (n = 3; MF = 40–50)], (3) two Fy*01 negatives [phenotype = Fy(a–b+), genotype not determined, MF = 5], (4) the proband’s father [phenotype = Fy(a+b–), genotype = Fy*01/Fy*01W.01, MF = 45], and (5) the proband’s mother [phenotype = Fy(a+b–), genotype = Fy*01/Fy*01, MF = 63].

Discussion

The Duffy blood group system consists of five antigens (the antithetical Fy+ and Fy; Fy3, Fy5, and Fy6) located on a multipass membrane glycoprotein known as DARC. The four common phenotypes, Fy(a+b–), Fy(a–b+), Fy(a+b+), and Fy(a–b–), are encoded by the Fy*01, Fy*02, and Fy*02N.01 alleles (Table 1). According to Howes et al.,1 the Fy*01 allele is most common in Asia, the Fy*02 allele is most common in Europe, and the Fy*02N.01 (null) allele is most common in Africa; heterogeneity of all three alleles is greatest in the Americas. A small percentage (2–3%) of Caucasians have the Fy*02W01 allele that codes for weakened expression of Fy+, Fy3, and Fy6. This Fy+ phenotype is caused by the c.265C>T mutation that results in a p.89 Arg to Cys amino acid substitution; this change appears to cause reduced levels of DARC in the RBC membrane.6 The two alleles currently described with this change are Fy*02W01 and Fy*02W02. Both are associated with a second mutation at c.298G>A, which results in a p.100 Ala to Thr change; the Fy*02W02 allele has an additional change at c.145G>T, which results in a p.49 Ala to Ser change. Two more recently described alleles in Caucasians, Fy*02W03 with a c.266G>A (p. 89 Arg to His) change and Fy*02W04 with a c.901C>T (p.303 Pro to Ala) change, also result in Fy(b+) phenotypes.5

Although rare mutations in the Fy*01 alleles have been described to cause null phenotypes,3,4,24 and there are reports of Southeast Asians with weak Fy+ on RBCs,25,26 until recently, no Fy*01W alleles had been reported. In 2015, Lopez et al. reported an Fy(a+b+) Australian Caucasian blood donor who was noted to have weak expression of Fy+. This phenotype was shown to be associated with a new allele, Fy*01W02, which had both the c.265C>T and c.298G>A mutations (as seen with Fy*02W01 and Fy*02W02). In 2013, we reported, at an AABB meeting, a recently transfused Vietnamese patient who was found to have an unusual allele, Fy*01W01, with only the critical c.265C>T change.6 Because of recent transfusions, the proband could not be phenotyped to determine if this allele was associated with weak Fy+ expression, but his parents were willing to be tested. The Fy(a+b–) mother had a normal Fy*01/Fy*01 genotype, but the Fy(a+b–) father had the new allele with a normal allele (Fy*01/Fy*01W01).

As the proband’s father typed 4+ with anti-Fy+ due to his Fy*01 allele, it would have been difficult to determine the strength of Fy+ by manual titrations, which have been shown to be poor predictors of antigen strength (e.g., zygosity).13 Flow cytometry, however, has been used successfully to study Duffy antigens—for example, to demonstrate weak expression of Fy+, Fy3, and Fy6 on Fy+ phenotype RBCs8,10,15,17,19 to distinguish zygosity (e.g., Fy*01/Fy*01 vs. Fy*01/Fy*02N.01)12,13,15, and to study Duffy antigen expression on cultured erythroid cells or reticulocytes,14,16,18,20 after RBC storage and leukocyte reduction,19 and on ovalocytes.20 Our flow cytometry studies with known examples of Fy*01 homozygotes and heterozygotes showed clear differentiation between the two groups. The proband’s father’s RBCs gave results that clearly fell in the heterozygous group, thus indicating that the Fy*01W01 allele...
codes for weak expression of Fy\(^a\). Interestingly, the proband’s mother’s RBCs gave results much weaker than any of the five Fy*01/Fy*01 homozygous controls (but still stronger than the eight Fy*01 heterozygous controls). She may have an unknown variant Fy*01 allele that codes for slightly weaker Fy\(^a\) expression.

In conclusion, we describe the first example of Fy(a+)\(^+\). The presence of this phenotype was predicted by Tournamille et al.\(^3\) based on the description by Shimizu et al.\(^2\) of some Thai individuals with weak Fy\(^a\). Unlike the alleles most commonly associated with Fy(b+) and the other allele recently described with Fy(a+\(^-\)), which have at least two mutations (c.265C>T and c.298G>A), the allele we are describing was only associated with one mutation (c.265C>T). This allele was discovered while performing molecular testing on samples from a recently transfused patient. Since the discovery of this allele, two more samples have been identified with the Fy\(^a\) change on an Fy*01 background at the Red Cross National Molecular Laboratory. Both samples were identified by indeterminate calls for the Duffy phenotype on microarray testing, much like the initial case report described here. The first, a female donor, race unknown, demonstrated both c.265C>T and c.298G>A changes on an Fy*01 background (like the Fy*01W02 allele described by Lopez et al.\(^*\)). The second case is a 49-year-old male patient, race unknown, with only the c.265C>T change located on the Fy*01 background, specifically the Fy*01W01 allele. As the use of molecular methods increases in the future, it is possible that more examples of Fy*01 alleles associated with Fy(a+)\(^+\) may be discovered.

**Acknowledgments**

The authors would like to acknowledge Debbie Bailey (former Assistant Director of the Immunohematology Reference Laboratory, American Red Cross, Southern California Region), for recognizing that flow cytometry would provide useful information in this case, and the late George Garratty (former Scientific Director at the American Red Cross, Southern California Region) for being on the forefront of applying flow cytometry to immunohematology.

**References**


Patricia A. Arndt, MS, MT(ASCP)SBB (corresponding author), Lead Technologist, Special Immunohematology Laboratory, American Red Cross Blood Services, Southern California Region, 100 Red Cross Circle, Pomona, CA 91768, patricia.arndt@redcross.org; Trina Horn, MS, MLT(ASCP)SBB, Laboratory Manager; Jessica A. Keller, MS, Laboratory Supervisor; Rochelle Young, Molecular Technologist I, American Red Cross National Molecular Laboratory, Philadelphia, PA; Suzanne M. Heri, MT(ASCP)SBB, Manager, Quality, Compliance, and Regulatory Affairs, Children’s Hospital Los Angeles, Los Angeles, CA; and Margaret A. Keller, PhD, Director, American Red Cross National Molecular Laboratory, Philadelphia, PA.

Notice to Readers
All articles published, including communications and book reviews, reflect the opinions of the authors and do not necessarily reflect the official policy of the American Red Cross.

For information concerning the National Reference Laboratory for Blood Group Serology, including the American Rare Donor Program, contact Sandra Nance, by phone at (215) 451-4362, by fax at (215) 451-2538, or by e-mail at Sandra.Nance@redcross.org

Attention:
State Blood Bank Meeting Organizers
If you are planning a state meeting and would like copies of Immunohematology for distribution, please send request, 4 months in advance, to immuno@redcross.org

Immunohematology is on the Web!
www.redcross.org/about-us/publications/immunohematology
For more information, send an e-mail to immuno@redcross.org
Clinical and reference lab characteristics of patients with suspected direct antiglobulin test (DAT)-negative immune hemolytic anemia

M.S. Karafin, G.A. Denomme, M. Schanen, and J.L. Gottschall

Clinical evidence of warm autoimmune hemolytic anemia is present in 1 percent to 10 percent of patients whose direct antiglobulin test (DAT) is negative. The clinical underpinnings associated with DAT-negative immune hemolysis are poorly understood, and the current study aimed to further define the clinical characteristics associated with this form of anemia.

A 19-question survey, requesting clinical information about each patient, was retrospectively mailed to all referring labs that had sent patient samples for an enhanced DAT evaluation from January 2011 through June 2013. An enhanced DAT evaluation involved a standard DAT and DATs performed using gel, polyethylene glycol, and 4°C low-ionic strength saline wash. We obtained detailed clinical information from 57 patients with an enhanced DAT investigation. Eighteen of these 57 patients (31.6%) were found to have a positive DAT, 11 (19.3%) of which were found to have a positive enhanced DAT (2 were positive by enhanced methods and negative by standard methods). The reported mean nadir hemoglobin for all 57 patients was 7.8 g/dL (range 3.2–12.7), and lactate dehydrogenase was 827.8 U/L (range 136–6917). Thirty-seven (88.1%) presented with a haptoglobin <10 mg/dL, and 21 (48.8%) reported spherocytes on peripheral smear. About half of the respondents reported using steroids as treatment for the anemia, and 4 of the 18 DAT-positive respondents (23.5%) changed their treatment plan because of the reference laboratory results. One patient died as a result of the reported hemolytic anemia (2.0%). We conclude that immune hemolysis detected by enhanced DAT methods is relatively common, and enhanced DAT methods are valuable tools in the diagnosis and management of patients with DAT-negative hemolytic anemia. Immunohematology 2015;31:108–115.

Key Words: DAT, autoantibodies, Coombs negative hemolytic anemia

The detection of red blood cell (RBC)-bound IgG and/or complement by a direct antiglobulin test (DAT) remains the main assay in the diagnosis of warm autoimmune hemolytic anemia (WAIHA).1 A positive DAT almost always exists in association with WAIHA and forms the basis for the serologic diagnosis.2–4 Several methodologies have been used in the detection of these globulins, but the most common and gold standard method is the conventional tube method.5 A negative DAT, however, does not exclude the diagnosis of WAIHA,4 and 1 percent to 10 percent of patients with clinical WAIHA have been reported to have a negative DAT with no detectible serum antibodies.6–9

There have been three hypotheses explaining WAIHA associated with a negative DAT. First, as the standard DAT can only detect about 150 to 200 molecules of IgG per RBC,6 these patients may carry a lower number of IgG molecules per RBC than the detection threshold for the test, yielding a false-negative tube DAT.10 Second, these patients may have a low-affinity IgG that dissociates from RBCs during the saline washes performed in the standard DAT procedure.2,11 Lastly, these patients may have clinically significant non-IgG immunoglobulins, such as IgA, that are not detected by the standard DAT.2,11

Whether or not the clinical entity of DAT-negative WAIHA differs significantly from DAT-positive WAIHA in terms of underlying pathogenic mechanisms, the severity of presentation, treatments, and clinical outcomes has been rarely studied.12,13 To increase our clinical knowledge of DAT-negative hemolytic anemias, we report the serologic results of patient samples that were submitted to our diagnostic reference laboratory for a DAT-negative WAIHA evaluation. We then correlated these reference laboratory results with the results of a 19-question survey that defined additional clinical and laboratory characteristics for these patients.

Materials and Methods

Serologic Detection

We retrospectively evaluated the results of all samples that were received from January 2011 through June 2013 for an enhanced DAT evaluation. The enhanced DAT evaluation at the BloodCenter of Wisconsin immunohematology reference laboratory involves a standard tube DAT, a gel, 4°C low-ionic-strength saline (LISS) wash, and a polyethylene glycol (PEG) DAT for all samples. All of these methods, including the standard DAT, are run in parallel. Standard DAT methods are well documented, and our lab used a polyspecific (rabbit and mouse) antihuman globulin (AHG) (Ortho, Raritan,
NJ), monospecific (monoclonal, mouse) anti-IgG (Immucor, Norcross, GA), anti-C3b, -C3d (Immucor), anti-C3d (Ortho Clinical Diagnostics, Raritan, NJ), and a 10% albumin control (Millipore, Kankakee, IL). The technique will not be further described here. For the enhanced methods, the gel test DAT was performed as described by the manufacturer (ID-Micro-Typing System, Ortho Clinical Diagnostics) using the MTS Anti-IgG card™ (rabbit). The 4°C LISS Wash (ELU-KIT II, Immucor) DAT used cold polyspecific AHG (rabbit and mouse antihuman globulin, Ortho Clinical Diagnostics), cold monoclonal anti-IgG (Immucor), and a cold 10% albumin control (Millipore). The 4°C LISS wash technique was performed by washing the sample RBCs four times with ice-cold (4°C) LISS using a refrigerated centrifuge. The RBCs were resuspended to a 2–5% suspension in LISS; one drop was added to two drops of cold anti-IgG or cold 10% albumin, centrifuged, and read immediately. The 10% albumin served as a control for the presence of a cold autoagglutinin; a positive result with the 10% albumin control invalidated the 4°C LISS wash test. The 20% PEG (Fisher Scientific, Fairlawn, NJ) technique (prepared in-house) was performed similarly to techniques described elsewhere.¹⁴

Patient Information
An institutional review board–approved 19-question survey was mailed to all referring labs that sent patient samples for an enhanced DAT evaluation from January 2011 until June 2013. Surveys were mailed 1 to 12 months after an enhanced DAT sample was received. The survey requested additional clinical information about each patient, including nadir hemoglobin, bilirubin, lactate dehydrogenase (LDH), haptoglobin, current diagnosis, treatment modality, and patient outcome. The questions included a combination of multiple choice and free response answers. The survey questions and answer choices are available in Figure 1.

Statistical Analysis
Patient and enhanced DAT data were summarized as means, standard deviations, and percents, as applicable. A comparison between those with and without a DAT-positive test result was performed. Frequency data were analyzed using a Fisher’s exact test, and continuous data were analyzed using an independent-sample t test. A p ≤ 0.05 was considered statistically significant.

Results
Serologic Findings
We received and performed an enhanced DAT on 447 samples from January 2011 until June 2013. The samples came from 213 female patients (47.7%) and 234 (52.3%) male patients. The average reported patient age for these reference lab samples was 51.1 years (±22.2 years) and ranged from 1 year to 99 years of age.

The summary of serological data is presented in Table 1. Of the 447 samples submitted for an enhanced DAT evaluation, 103 (23.0%) were positive for at least one standard DAT method, and of these, 28 (27.2%) were found to be positive for only complement. We further identified that 107 (23.9%) of the 447 samples were positive for at least one of the enhanced methods. Only 37 (34.6%, 8.3% overall) of the 107 samples were positive with an enhanced method but negative with the standard polyspecific DAT method, and only 8 (7.5%) samples were positive with an enhanced method when positive for only complement using standard methods. Five (13.5%) of the 37 were positive for a combination of enhanced methods, 18 (48.6%) were positive only with gel, 14 (37.8%) were positive only with 4°C LISS, and none were positive with PEG alone (two samples were positive by PEG and gel).

<table>
<thead>
<tr>
<th>Table 1. Summary of the battery of serologic tests used for a DAT-negative autoimmune hemolytic anemia evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Results (N=447)</td>
</tr>
<tr>
<td>Any positive standard polyclonal AHG</td>
</tr>
<tr>
<td>Any positive standard C3 or IgG</td>
</tr>
<tr>
<td>Any positive enhanced test</td>
</tr>
<tr>
<td>• Standard DAT negative</td>
</tr>
<tr>
<td>Any positive for multiple enhanced methods</td>
</tr>
<tr>
<td>• Standard DAT negative</td>
</tr>
<tr>
<td>Any gel test positive</td>
</tr>
<tr>
<td>• Standard DAT negative</td>
</tr>
<tr>
<td>Any 4°C LISS test positive</td>
</tr>
<tr>
<td>• Standard DAT negative</td>
</tr>
<tr>
<td>Any PEG test positive</td>
</tr>
<tr>
<td>• Standard DAT negative</td>
</tr>
</tbody>
</table>

DAT = direct antiglobulin test; AHG = antihuman globulin; LISS = low-ionic-strength saline; PEG = polyethylene glycol.

Clinical Findings
Of the 447 surveys mailed, we received additional clinical information regarding 57 DAT-negative patients (response rate: 12.6%). There were more female than male patients (37 female, 64.9%) in this cohort, and the average reported age...
was 48 (±25.2) years with a range of 1 to 90 years. Of the 57 patients, 39 (68.4%) were negative by all testing methods. Of those who tested positive, 16 (28.1%) had a positive standard polyspecific DAT, with 4 (7.0%) being positive for the standard polyspecific DAT alone, 6 (10.5%) being positive for IgG alone, 3 (5.3%) being positive for C3 alone, and 3 (5.3%) having both IgG and C3 coating their RBCs. Eleven of the 18 patients with a positive DAT (61.1%) had at least one positive enhanced DAT (4 [22.2%] 4°C LISS positive, 6 [33.3%] PEG positive, and 11 [61.1%] gel positive). Only 2 (18.2%) of the 11 respondents had a positive enhanced DAT (both gel only) with a negative standard polyspecific DAT in our laboratory (Table 2).
Antibody specificities were further classified by the reference lab when possible (Table 2). Of the 18 total respondents who had a positive DAT (enhanced and/or standard), serum or eluate evidence of warm autoantibodies was noted in 9 (50%) of these patients, followed by 5 (27.8%) cold autoantibodies, 3 (16.7%) "low affinity" warm autoantibodies (suggested by a positive enhanced LISS DAT, and negative standard monoclonal IgG DAT), and 1 (5.6%) alloantibody (anti-E). Two of the 18 patients were also found to have evidence of a drug-induced hemolytic anemia (cefotetan and carboplatin) as the cause of their DAT-negative evaluations. The two patients who had a negative standard polyspecific DAT, but a positive enhanced DAT, were both suggested to have warm autoantibodies (one was also found to have an anti-I in the serum).

A summary of selected survey questions for the 57 patients is presented in Table 3. Overall, patients presented with anemia (hemoglobin mean 7.8 g/dL ± 2.1, range 3.2–12.7 g/dL), hyperbilirubinemia (mean 4.1 mg/dL ± 4.32), and evidence of hemolysis, as demonstrated by an elevation in LDH, low haptoglobin, and the presence of spherocytes. A majority of respondents reported that the patient did not have a known disease process associated with a hemolytic anemia (32 respondents, 56.1%), and of those who did, hematologic malignancy (lymphoma, chronic lymphocytic leukemia, chronic myelocytic leukemia, B-cell or T-cell acute lymphocytic leukemia, multiple myeloma, hemophagocytic syndrome) was the most commonly reported diagnosis (15 respondents, 26.3%). Other reported associated diagnoses included colon/lung/ovarian cancer, sickle cell disease, artificial heart valves, and hypothyroidism. About half of the patients were treated with steroids for their anemia, and most started this therapy prior to the enhanced DAT evaluation (64.3%). After the DAT evaluation was reported, 85.7 percent (42 respondents) reported not changing their selected therapies, and 77.6 percent (38 respondents) did not alter their reported diagnosis. The most common reported diagnosis after DAT was hematologic malignancy (12 patients, 25.5%), followed by WAIHA (8 patients, 17.5%), immune hemolysis (5 patients, 10.5%), or sepsis (5 patients, 10.5%). Less frequently reported diagnoses included solid organ malignancy, microangiopathic hemolysis, mechanical hemolysis, congenital red cell defects, prematurity,
coronary artery disease, occult bleeding, and vasculitis. Most patients recovered or became stable with treatment (64.7%), and while 14 patients were reported as deceased, only 1 death was reported as caused by the hemolytic process (1.8%). The average recovery time was 2.7 months, with a reported range of 1 week to 1 year.

We statistically compared the survey responses of those 18 patients who were found to have a positive reference lab DAT (any method) from those who did not. While the numbers were small, we found no significant difference in patient gender distribution or age (Table 3). While we found that those with a positive DAT had a lower mean nadir hemoglobin, higher mean LDH, and higher mean bilirubin than those who had a negative DAT, none of these differences reached statistical significance \(p > 0.05\). Moreover, the frequency of reported associated diagnoses, treatments used, and patient outcome did not differ based on the DAT result. In contrast, we did find that there was a significant difference in physician responses to the results. Specifically, we found that 7 of 17 (41.2%) respondents changed their patient’s working diagnosis when the DAT was reported to be positive, whereas only 4 of 32 (12.5%) reported a change in diagnosis after a negative DAT result \(p = 0.03\).

We also found a trend where more respondents (DAT positive: 4 of 17, 23.5%, DAT negative: 3 of 32, 9.4%, \(p = 0.2\) changed

### Table 3. Summary of selected survey responses from the labs requesting an enhanced evaluation for a reported DAT-negative hemolytic anemia \(N=57\)

<table>
<thead>
<tr>
<th>Survey Question</th>
<th>Overall responses ((N=57))</th>
<th>Respondents with a negative DAT ((N=39))</th>
<th>Respondents with a positive DAT ((N=18))</th>
<th>(p) value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient gender</td>
<td>Male: 20 (35.1%)</td>
<td>Male: 13 (33.3%)</td>
<td>Male: 7 (38.9%)</td>
<td>0.77</td>
</tr>
<tr>
<td></td>
<td>Female: 37 (64.9%)</td>
<td>Female: 26 (66.7%)</td>
<td>Female: 11 (61.1%)</td>
<td></td>
</tr>
<tr>
<td>Patient age — avg (± sd)</td>
<td>48.0 (± 25.2)</td>
<td>47.8 (± 27.5)</td>
<td>48.4 (± 20.1)</td>
<td>0.93</td>
</tr>
<tr>
<td><strong>Lab Values — avg (± sd)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nadir hemoglobin (g/dL)</td>
<td>7.8 (± 2.1)</td>
<td>8.2 (± 2.3)</td>
<td>7.0 (± 1.5)</td>
<td>0.051</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>827.8 (± 1164.6)</td>
<td>778.6 (± 856.7)</td>
<td>947.1 (± 1737.4)</td>
<td>0.65</td>
</tr>
<tr>
<td>Total bilirubin (mg/dL)</td>
<td>4.1 (± 4.3)</td>
<td>3.5 (± 4.2)</td>
<td>4.96 (± 4.5)</td>
<td>0.27</td>
</tr>
<tr>
<td>Haptoglobin (# reported below the lower limit of detection)</td>
<td>37/42 (88.1%)</td>
<td>21/28 (75.0%)</td>
<td>10/14 (71.4%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Spherocytes present on smear</td>
<td>21/43 (48.8%)</td>
<td>14/28 (50.0%)</td>
<td>7/15 (46.7%)</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>Associated Diseases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphoma</td>
<td>5/23 (21.7%)</td>
<td>4/15 (26.7%)</td>
<td>1/8 (12.5%)</td>
<td>0.62</td>
</tr>
<tr>
<td>Lupus</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>Mycoplasma</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>Mononucleosis</td>
<td>1/23 (4.3%)</td>
<td>1/15 (6.7%)</td>
<td>0</td>
<td>1.0</td>
</tr>
<tr>
<td>Viral syndrome</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>Other (i.e., ALL, CLL)</td>
<td>18/23 (78.3%)</td>
<td>11/15 (73.3%)</td>
<td>7/8 (87.5%)</td>
<td>0.62</td>
</tr>
<tr>
<td><strong>Treatments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steroids</td>
<td>25/50 (50%)</td>
<td>13/28 (46.4%)</td>
<td>12/22 (54.5%)</td>
<td>0.8</td>
</tr>
<tr>
<td>Rituximab</td>
<td>3/50 (6%)</td>
<td>1/28 (3.6%)</td>
<td>2/22 (9.1%)</td>
<td>0.6</td>
</tr>
<tr>
<td>Splenectomy</td>
<td>1/50 (2%)</td>
<td>1/28 (3.6%)</td>
<td>0</td>
<td>1.0</td>
</tr>
<tr>
<td>IVIG</td>
<td>3/50 (6%)</td>
<td>0</td>
<td>3/22 (13.6%)</td>
<td>0.1</td>
</tr>
<tr>
<td>Plasma exchange</td>
<td>2/50 (4%)</td>
<td>0</td>
<td>2/22 (9.1%)</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>14/51 (27.5%)</td>
<td>7/35 (20.0%)</td>
<td>7/16 (43.8%)</td>
<td>0.1</td>
</tr>
<tr>
<td>Active disease (stable)</td>
<td>16/51 (31.4%)</td>
<td>12/35 (34.3%)</td>
<td>4/16 (25.0%)</td>
<td>0.5</td>
</tr>
<tr>
<td>Active disease (unstable)</td>
<td>4/51 (7.8%)</td>
<td>3/35 (8.6%)</td>
<td>1/16 (6.3%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Disease resolved</td>
<td>17/51 (33.3%)</td>
<td>13/35 (37.1%)</td>
<td>4/16 (25.0%)</td>
<td>0.5</td>
</tr>
</tbody>
</table>

DAT = direct antiglobulin test; LDH = lactate dehydrogenase; ALL = acute lymphocytic leukemia; CLL = chronic lymphocytic leukemia; IVIG = intravenous immunoglobulin; sd = standard deviation.
treatment plans when the DAT was reported to be positive. Of those who changed their treatment plan because of a positive DAT result, 50 percent (2/4) specifically added steroids as a treatment, and 1 discontinued steroid therapy (patient with the drug-induced hemolytic anemia). Only one of the three respondents (33%) who changed a treatment plan because of the negative DAT result specifically reported discontinuing steroid use.

Discussion

The current study aimed to provide a clinical-pathologic correlation for patients with suspected immune DAT-negative hemolytic anemia, regardless of the cause. Of the 447 samples evaluated during the study interval, we found that about 1 in 4 DAT-negative referrals were positive with enhanced methods. This finding was complicated by the fact that most of these positive studies were also positive with standard DAT methods in our reference lab and that only 8.3 percent of samples were positive using DAT-enhanced methods alone. Our survey revealed that the clinical characteristics of patients with a DAT-positive and DAT-negative evaluation did not differ significantly, though knowledge of a positive enhanced DAT result caused significantly greater changes to the patient's reported diagnosis, and altered treatment plans.

The phenomenon of clinically evident WAIHA with a negative DAT has been known for decades. Worledge and Blajchman (1972) reported that 3 percent of 333 patients with AIHA were DAT negative; Chaplin reported a similar incidence; Petz and Garratty et al. found that many cases resulted in disease remission or stability. The differences in technique and methodology can dramatically influence the quality of hospital laboratory DAT results. In our laboratory, we also found that 23 percent of samples submitted for a DAT-negative hemolytic anemia had a positive standard DAT, supporting these previous observations. Second, we found a similar proportion of positive DAT results using enhanced methods. In the study performed by Leger et al., 4.9 percent of samples were positive by LISS alone, 2.0 percent by polybrene alone, and 0 percent by gel alone. When excluding those that were positive by standard DAT methods, we also found that 3.1 percent of samples were positive only with 4°C LISS, none were positive with PEG alone, and 4.0 percent were positive only with gel.

To our knowledge, our study is the first in the U.S. to evaluate clinical information on a cohort of 57 patients with a suspected DAT-negative hemolytic anemia and then correlate these findings with reference laboratory serologic results. The findings from our survey are consistent with, and expand upon, the observations from other previous studies. Specifically, DAT-negative WAIHA has been associated with non-Hodgkin's lymphomas, certain chemotherapeutic drugs (such as fludarabine, cyclophosphamide, and rituximab), certain hematopoietic stem cell transplants, autoimmune diseases such as Sjogren syndrome, kidney transplants, certain solid organ malignancies, and pregnancy. Similarly, our 18 DAT-positive respondents reported that their hemolytic anemia was associated with acute leukemia status post–bone marrow transplant, myelodysplastic syndrome, and sickle cell disease.

We also confirmed that steroids are the most common treatment for our patient cohort and that these treatments generally resulted in disease remission or stability. This observation is consistent with what has been previously reported. Case studies reveal that patients with DAT-negative hemolytic anemia are generally responsive to steroids, but recurrences of the hemolytic anemia have been reported. In their retrospective review, they identified 154 patients over a 7-year period with DAT-negative hemolytic anemia. They found that 91 percent responded to steroids, 70 percent entered remission in 4 weeks, and 84 percent survived at least 1 year. While fewer of our cohort reported that they used steroids (about 50%), we still found that when steroids were used, more than half demonstrated remission or stability of disease. The differences between our study, and that done by Kamesaki et al. are likely
attributable to the differences in the lab methods used to detect DAT-negative hemolytic anemia and the differences in how we categorized DAT-positive from DAT-negative patient cohorts.

Our study has some notable limitations. First, despite our best efforts, our survey response rate was quite low. Identified reasons for this low response rate included unexpected changes to physician address that could not be further clarified, and large numbers of corporate referring labs that did not have access to patient data. The limited response rate added a possible selection bias that cannot be fully accounted for. However, we feel that our data are generally representative, since our findings are similar to other published literature on this topic. Second, most of our respondents had DATs that were positive by both the enhanced and the standard methods. Consequently, the subsequent patient data reviewed does not represent the clinical characteristics of truly DAT-negative hemolytic anemia. What we can say, however, is that the data reviewed here likely represent the characteristics of those patients who had a negative DAT at some point in their diagnostic workup and were suspected to have a DAT-negative hemolytic anemia. Lastly, while we evaluated hundreds of DAT-negative samples, we could only provide clinical correlations for a small number of cases. Because of sample size and the varying test methods used, we were not able to determine the cause for the negative DAT in these patients (i.e., low number of IgG molecules or significant non-IgG immunoglobulins). IgA-induced hemolytic anemia, specifically, was not represented in our cohort, and only two cases of low-affinity antibodies (LISS positive, monoclonal IgG negative) were evaluated in our survey sample.

In conclusion, this study suggests that using a battery of enhanced methods to evaluate cases of possible DAT-negative autoimmune hemolytic anemia is valuable, and changes to diagnosis and treatment plans were identified when a DAT-positive result was obtained from a formerly DAT-negative patient. Moreover, the use of enhanced techniques in the 103 cases with positive standard DATs increased the confidence that immunoglobulin was truly binding to red cells. Clearly, no single test can be used to predict the presence of significant autoantibodies, and our study supports an increasing body of literature that DAT-negative and DAT-positive hemolytic anemias appear similar in etiology, treatment, and general outcome. Additional larger prospective studies are needed to further elucidate the qualities that make patients with DAT negative hemolytic anemia unique.

References


Matthew S. Karafin, MD, Associate Medical Director (corresponding author), Medical Science Institute, BloodCenter of Wisconsin, 638 N. 18th Street, Milwaukee, WI 53201, and Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53201, matthew.karafin@bcw.edu; Gregory A. Denomme, PhD, Director; Michael Schanen, SBB, Immunohematology Reference Lab, BloodCenter of Wisconsin, Milwaukee, WI; and Jerome L. Gottschall, MD, Senior Medical Director, Medical Science Institute, BloodCenter of Wisconsin, and Department of Pathology, Medical College of Wisconsin, Milwaukee, WI.
Blocked D phenomenon and relevance of maternal serologic testing

A. Jain, V. Kumawat, and N. Marwaha

A blood requisition for double-volume exchange transfusion was received for a 2-day-old male child born to a 29-year-old multiparous female (P_2002) referred to our institute having neonatal jaundice with encephalopathy; no maternal sample was received. The neonatal blood sample was typed as group A, D−, and the direct antiglobulin test (DAT) was strongly positive (4+) using the gel method. Mono-specific DAT showed the presence of IgG antibodies on neonatal red blood cells (RBCs). Acid elution and gentle heat elution (at 56°C) confirmed the presence of anti-D on neonatal RBCs. The baby received two exchange transfusions with group O, D−, packed RBCs compatible with his own serum. Later, on day 3, the neonate’s mother was typed as group AB, D−, and her serum revealed the presence of alloanti-D, -C, and -S reactive in the anti-human globulin phase. The anti-D titer was 1024. This report highlights the “blocking” phenomenon caused by maternal anti-D in a case of hemolytic disease of fetus and newborn with a positive DAT. *Immunohematology* 2015;31:116–118.

**Key Words:** blocked D phenomenon, maternal serologic testing, antibody screening

Of all red blood cell (RBC) antigens, D is second only to ABO in importance in blood transfusion. The Rh antigens are fully expressed at the time of birth, unlike the weak expression of ABO in neonates. A cumulative dose of not more than about 0.03 mL RBCs is capable of inducing primary D immunization. False-negative typing results caused by potent antibody-blocking antigen sites are uncommon when using modern monoclonal blood-grouping reagents. Nevertheless, it is well known that blocking of fetal D with potent maternal anti-D (also known as “blocked D phenomenon”) can occur and attempted typing of these fetal RBCs using IgM anti-D can yield false-negative results. We report here a case of blocked D in a neonatal blood sample in a suspected case of Rh hemolytic disease of fetus and newborn (HDFN) that was detected in our hospital.

**Case Report**

A 2-day-old male child was admitted through the pediatric emergency department of our institute after referral from a nearby district hospital with a diagnosis of neonatal jaundice with encephalopathy. The neonate was born to a 29-year-old multiparous female (P_2002) with a previous live male child who was currently 2 years old. First delivery was unsupervised full-term vaginal delivery with no history of neonatal jaundice. No anti-D immunoprophylaxis was given at the first delivery. Index neonate was also born after a full-term normal vaginal delivery with a birth weight of 3 kg. Total serum bilirubin was 25 mg/dL when the neonate was admitted through the pediatric emergency department. The neonate was lethargic with excessive crying and poor feeding. Blood requisition for double-volume exchange transfusion was received at our blood bank without the mother’s sample since she was not available.

**Results**

In the pre-transfusion testing laboratory, the neonatal RBCs were typed for ABO and D by the conventional tube method using commercially available reagents; this showed the blood type as group A, D−. The direct antiglobulin test (DAT) was performed using the gel method (Anti-IgG + C3d, LISS-Coombs AHG Card, Bio-Rad, Cressier, Switzerland), which gave a strong positive (4+) result. Monospecific DAT (DC screen II, Bio-Rad) showed the presence of IgG on the neonatal RBCs (Fig. 1). Subsequently, the D typing was repeated with anti-D sera from various manufacturers and was found to be negative with all of them (Fig. 2). Antibody screening (Diacell, Bio-Rad) and identification (Diapanel, Bio-Rad) of the neonate’s serum revealed presence of anti-D. Acid elution (Diacidel, Bio-Rad) and gentle heat elution (at 56°C) of the neonate’s RBCs confirmed the presence of anti-D on the RBCs.

Because this was an emergency situation and also because of the limited sample volume, extended Rh-matched (C, c, E, e) and K-matched, compatible group O, D−, RBCs along with group AB, D+, plasma were issued for exchange transfusion. After two exchange transfusions, the bilirubin lowered to 17.7 mg/dL from 24.6 mg/dL and the hematocrit improved from 30 percent to 50 percent. The neonate’s mother was subsequently available on day 3, and she was typed as group AB, D−, with a probable Rh phenotype of rr (dce/dce) (Table 1). Antibody...
screening (Diacell) and identification (Diapanal) of maternal serum revealed presence of multiple alloantibodies. Testing with enzyme-treated cells and using the “select cell process” confirmed the presence of alloanti-D, -C, and -S in maternal serum. These were found to be reactive in the antihuman globulin (AHG) phase. Maternal titer of anti-D was found to be 1024 by the conventional tube method. The father was typed as group B, D+, with an extended typing of C+, c–, E–, e+.

On day 4 of life, in view of rising bilirubin (21.5 mg/dL), a third exchange transfusion was done with an AHG phase-compatible, group O, D–, packed RBC component that was Rh-matched (C, c, E, e), K-matched, and also S–. The baby subsequently recovered well and was finally discharged from the hospital on day 8 of life.

**Discussion**

ABO and D testing can be regarded as the most important serologic tests performed in transfusion services on pretransfusion samples. Of the alloantibodies that have been implicated in HDFN, anti-D is usually associated with the most severe disease. In our case, despite the mother being sensitized to three clinically significant alloantibodies, it was primarily the anti-D that was responsible for HDFN, because it was the only antibody to be identified in the neonatal red cell eluate.

The blocking phenomenon caused by maternal anti-D should be suspected in a case of Rh-HDFN if fetal or neonatal RBCs give a strongly positive result in a DAT but a negative result on D typing with saline reactive anti-D. This phenomenon may lead to a delay in making an antenatal or postnatal diagnosis of Rh-HDFN by routine serologic investigation. The first description of D blocking phenomenon was given by Wiener in 1944. Recently, Verma et al. described the blocked D phenomenon on fetal RBCs from a group AB, D–, female who had a high anti-D titer (256) and was planned for intrauterine transfusion because of fetal anemia. In their report, the fetal blood sample gave a strong positive DAT (4+) using the gel method and was typed as D–. The fetal parameters improved after the transfusion, but

---

**Table 1. Extended phenotyping**

<table>
<thead>
<tr>
<th></th>
<th>C</th>
<th>c</th>
<th>E</th>
<th>e</th>
<th>K</th>
<th>Jk⁺</th>
<th>Jk⁻</th>
<th>Fy⁺</th>
<th>Fy⁻</th>
<th>Le⁺</th>
<th>Le⁻</th>
<th>M</th>
<th>N</th>
<th>S</th>
<th>s</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother</td>
<td>Neg</td>
<td>4+</td>
<td>Neg</td>
<td>4+</td>
<td>Neg</td>
<td>4+</td>
<td>3+</td>
<td>2+</td>
<td>2+</td>
<td>Neg</td>
<td>Neg</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>Neg</td>
</tr>
<tr>
<td>Father</td>
<td>4+</td>
<td>Neg</td>
<td>Neg</td>
<td>4+</td>
<td>Neg</td>
<td>4+</td>
<td>Neg</td>
<td>2+</td>
<td>2+</td>
<td>Neg</td>
<td>4+</td>
<td>4+</td>
<td>2+</td>
<td>3+</td>
<td>Neg</td>
</tr>
<tr>
<td>Neonate</td>
<td>4+</td>
<td>Neg</td>
<td>Neg</td>
<td>4+</td>
<td>Neg</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
</tr>
</tbody>
</table>

nd = not done.
the mother developed an additional alloantibody (anti-Jk^b). Sulochana et al.\(^6\) described a case in which a D-negative result was found repeatedly in a newborn baby with severe HDFN born to a second gravida group B, D−, mother. The authors reported that the mother had an anti-D titer of 1024 along with alloanti-C, which was determined only after the baby was born and underwent exchange transfusions. There was no antenatal follow-up of the patient. In our case as well, the antibody specificities could be completely determined only after testing the maternal sample. We found three alloantibodies (anti-D, anti-C, and anti-S) that were reactive in the AHG phase and thus were clinically significant. The paternal RBC typing revealed that he was D+, C+, and S+, which might have been inherited by the fetus causing alloimmunization in the mother. The baby recovered well after three exchange transfusions and was discharged. The serologic testing for “weak D” on the neonate’s RBCs during the period of positive DAT was not of much significance. However, the later follow-up of the baby’s RBCs for D typing and extended phenotyping once the transfused cells had cleared from the baby’s circulation could not be performed. Thus, a regular antibody screen and follow-up in the antenatal period is of utmost importance to ensure appropriate fetal management.

The blocking phenomenon is not limited to anti-D. Blocking phenomenon caused by Kell blood group antibodies have been reported (e.g., two cases of false-negative K1 typing of fetal cells caused by blocking maternal IgG anti-K^+\(^6\)–\(^8\)). With the immunogenicity of D being only second to ABO, accuracy in D typing is critical in transfusion medicine. British Committee for Standards in Haematology\(^9\) antenatal grouping and screening guidelines provide guidance to identify potentially harmful cases of HDFN.

In conclusion, the blocking phenomenon caused by maternal anti-D should be suspected in a possible case of Rh-HDFN if fetal or neonatal RBCs give a strongly positive result in a DAT but typing for D is negative.

**References**


Ashish Jain, MD, Assistant Professor (corresponding author), Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Sector 12, Chandigarh 160012, India, ashishjain16@gmail.com; Vijay Kumawat, MD, Senior Resident, Department of Transfusion Medicine; and Neelam Marwaha, MD, FAMS, Professor and Head, Department of Transfusion Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Anti-Jk3 in a Filipino man

S. McCaskill, S. Wise, and S. Tinsley

A 62-year-old Filipino man with a history of chronic obstructive pulmonary disease, hypertension, and hyperlipidemia was admitted to the emergency department at Hospital A with recurrent fevers, weakness, and jaundice. The patient was evaluated and eventually discharged with a diagnosis of possible drug-induced hepatitis. One month later, the patient was admitted to Hospital B for recurrent fevers and weakness. The patient’s hemoglobin was 3.8 g/dL. Six units of packed red blood cells (RBCs) were ordered for transfusion. The patient’s sample typed as group B, D+, and the antibody screen was negative. All six units of packed RBCs appeared compatible (at immediate spin) and were transfused to the patient. His hemoglobin level 4 days post-transfusion was 9.3 g/dL, and the patient was discharged. The patient returned after a week for follow-up and his hemoglobin was found to have dropped to 8.5 g/dL, which continued to fall until it reached 7.0 g/dL. Additional packed RBCs were ordered for transfusion. During subsequent pre-transfusion compatibility testing, the antibody screen was found to be positive (all screening cells reactive at the antihuman globulin phase). An antibody identification panel was performed. The patient’s serum was found to react with all panel cells tested, including the autocontrol tube. A direct antiglobulin test revealed the presence of both anti-IgG and anti-C3 coating the patient’s RBCs. The specimen was then sent to a reference laboratory for further testing. Results from the reference lab testing revealed the presence of anti-Jk3 in the patient’s serum. The patient was placed on steroids, and his reticulocyte count increased with no further signs of extravascular hemolysis. No additional transfusions were necessary. He was eventually discharged with a hemoglobin of 13.6 g/dL. The purpose of this case study is to report the findings of an extremely rare but clinically significant antibody, anti-Jk3.

**Key Words:** magnetic resonance cholangiopancreatography, MRCP, antihuman globulin, AHG, direct antiglobulin test, DAT, intravenous immunoglobulin, IVIG, delayed hemolytic transfusion reaction, DHTTR, breakpoint cluster region protein, BCR, Janus kinases 2 gene, JAK2, Abelson murine leukemia viral oncogene homolog 1, ABL1

The Kidd blood group system is defined by two antigens, Jk\(^a\) and Jk\(^b\), that yield four different phenotypes: Jk(a+b+), Jk(a+b–), Jk(a–b+), and Jk(a–b–). Jk(a–b–) is also known as Jk:\--3 or the Jk\(_{null}\) phenotype. The antigens Jk\(^a\) and Jk\(^b\) were discovered by Allen, Diamond, and Niedziela in 1951\(^1\), and the Jk(a–b–) phenotype was discovered soon after by Pinkerton and Mermod in 1959\(^2\). Individuals with the Jk(a–b–) phenotype lack both Jk\(^a\) and Jk\(^b\). The Jk(a–b–) phenotype can result from the homozygous inheritance of recessive alleles that produce neither Jk\(^a\) nor Jk\(^b\) or from the inheritance of a dominant inhibitor gene, In(Jk), reported to have no association with the Jk locus but causes a suppression of the expression of Kidd antigens.\(^3\) The Jk(a–b–) phenotype is seen more frequently in people of Polynesian, Filipino, and Chinese descent.\(^4\)

The first reported occurrence of the Jk(a–b–) phenotype was detected in a Filipino woman with Chinese and Spanish ancestry.\(^5\) The Jk(a–b–) phenotype is rare among white and black populations and is more common among Polynesians, Filipinos, and Chinese.\(^5,6\) The Jk(a–b–) phenotype frequency among the white population is less than 0.1 percent.\(^6\) In Taiwan, the Jk(a–b–) phenotype was found to be 1.0 percent among the Rukai tribe and 1.2 percent among the Paiwan tribe.\(^7\) Among Polynesians, the Jk(a–b–) phenotype frequency is 1.4 percent.\(^8\) The Jk(a–b–) phenotype has also been reported to occur more frequently in Indian, Brazilian, Japanese, and Thai populations.\(^8\)

Alloantibodies to Kidd antigens are clinically significant in transfusion recipients and women who are pregnant. The antibodies are produced in reaction to antigen exposure during a previous transfusion or pregnancy and remain in low titer in plasma until secondary exposure occurs. Kidd antibodies are capable of binding complement and are known to cause both immediate and delayed hemolytic transfusion reactions (DHTTRs) as well as hemolytic disease of the fetus and newborn (HDFN). The production of anti-Jk3 occurs only in individuals who have inherited recessive alleles causing the Jk(a–b–) phenotype; those who have inherited the dominant inhibitor gene In(Jk) cannot make anti-Jk3.\(^9\) Anti-Jk3 is best detected by the indirect antiglobulin test (IAT) and can be enhanced with enzyme pretreatment of RBCs used in antibody identification procedures.

**Case Report**

A 62-year-old Filipino man with a history of chronic obstructive pulmonary disease, hypertension, and hyperlipidemia was admitted to the emergency department at Hospital A with recurrent fevers, weakness, and jaundice. His liver function tests were elevated: aspartate aminotransferase (AST) = 64 IU/L (normal 1–40 IU/L),...
alanine aminotransferase (ALT) = 85 IU/L (normal range 7–567 IU/L), alkaline phosphatase (ALP) = 561 IU/L (normal range 44–147 IU/L), total bilirubin = 1.8 mg/dL (normal range 0.3–1.9 mg/dL), and an ultrasound showed some evidence of liver disease of uncertain cause. He underwent magnetic resonance cholangiopancreatography (MRCP), which showed no evidence of biliary obstruction/dilation or stones. Other serologic testing for infectious disease markers and autoimmune disorders was negative.

His hemoglobin was low, between 7 and 9 g/dL (normal range elderly male: 12.4–14.9 g/dL), and serum ferritin was greater than 2,000 (normal range male: 12–300 ng/mL). The patient’s peripheral blood smear was unremarkable with the exception of leukocytosis and the presence of target cells. Target cells were suggestive of biliary obstruction/dilation or stones, but this was ruled out by MRCP. The patient also had a high serum ferritin level, which is a common finding in patients with liver disease. In a patient experiencing a DHTR, schistocytes and reticulocytosis may be present on the peripheral blood smear; they were absent in this patient. The bone marrow biopsy did show hypocellularity with atypical megakaryocytic hyperplasia and erythroblastopenia. An IgG plasma cell dyscrasia was also noted with 13 percent to 15 percent plasma cells (flow and immunofixation positive, fluorescence in situ hybridization [FISH] negative) with serum protein electrophoresis of 1.5 (reference range: 0.7–1.5 g/dL). Results of genetic testing revealed the patient to be JAK2-negative and FISH for BCR/ABL—negative, but positive for three copies of ABL1 w/trisomy 9/9q, which can be associated with BCR/ABL1-negative chronic myeloproliferative disease, myelodysplastic syndrome, acute myelogenous leukemia, and, rarely, B-cell acute lymphoblastic leukemia. Tests for parvovirus B19 (serum IgM and immunohistochemistry) on the bone marrow were negative, but the presence of intra-nuclear eosinophilic inclinations in the bone marrow suggested possible parvovirus infection.

The patient was subsequently discharged. The patient was admitted to Hospital B 1 month later with recurrent fevers and weakness. His hemoglobin was 3.8 g/dL. A peripheral blood smear showed signs of leukocytosis (29K) (normal range 4.5–11.0K) and thrombocytosis (normal range: 150–450K). A bone marrow biopsy showed hypercellularity with atypical megakaryocytes, hyperplasia, and erythroblastopenia. IgG plasma cell dyscrasia was noted with 13 percent to 15 percent plasma cells and the presence of eosinophilic inclusions suggestive of parvovirus infection. Serologic tests for parvovirus were negative. A type and crossmatch for six units of blood was ordered. The patient was found to be group B, D+–; the antibody screen was negative; and all six units ordered appeared compatible (immediate spin crossmatch). The patient received all six units of type-specific, packed red blood cells (RBCs) with no signs of adverse reaction. The patient was also given intravenous immunoglobulin (IVIG) for the suspected parvovirus infection. His hemoglobin level 4 days post-transfusion was 9.3 g/dL, and he was discharged 10 days from date of admittance.

The patient returned to Hospital B 1 week later for follow-up with an oncologist, and his hemoglobin was found to have dropped to 8.5 g/dL, which continued to fall until it reached 7.0 g/dL (approximately 19 days after transfusion). Additional packed RBCs were ordered for transfusion. During subsequent compatibility testing procedures, the antibody screen was found to be positive with all screening cells at the antihuman globulin (AHG) phase of testing. An antibody identification panel was performed. The patient’s serum was found to react with all panel cells tested including the autocontrol tube at the AHG phase of testing. A direct antiglobulin test (DAT) panel was performed using polyspecific (anti-IgG + anti-C3) and monospecific AHG reagents (anti-IgG, anti-C3). The results of the DATs showed both anti-IgG and anti-C3 coating the patient’s RBCs. The specimen was then sent to a reference laboratory for further testing. Results from the reference lab testing using a polyethylene glycol (PEG)-IAT method revealed the presence of anti-Jk3 in the patient’s serum. An elution was not performed because the patient had not been transfused within the previous 2 weeks. Aliquots of the patient’s serum were adsorbed using allogeneic cells. Clinically significant antibodies to other major blood group antigens were excluded by the PEG-IAT using the adsorbed plasma. Phenotyping was performed on autologous neocytes recovered by microhematocrit centrifugation. Results of the phenotyping showed the patient to be Jk(a–b–). Genomic sequencing was also performed on the patient’s RBCs to determine the genotype that would allow for the prediction of the patient’s phenotype. Results of the genetic testing revealed the presence of two variant alleles that were detected by JK-cDNA analysis and genomic sequencing. Jk*02N.01 carried the intron 5c.342-1g>a variant that is associated with exon 6 skipping and a null Jk(b–) phenotype. The Jk*01 allele carried the two known changes of c.130G>A and c.893G>A, not normally reported on the same allele. The JkC.130A single-nucleotide polymorphism (SNP) is associated with weakened antigen expression, and the c.893A SNP is associated with a null Jk(a–) phenotype. It was recommended, if transfusion was necessary, to select ABO/Rh compatible units negative for both JkA and JkB.
This case report focuses on a clinically significant but infrequent antibody known as anti-Jk3. The clinical significance of anti-Jk3 is that it displays weak reactivity in vitro but has the capacity to induce severe RBC destruction in vivo in the presence of Jk^a and/or Jk^b. Anti-Jk3 will present as a “panagglutinin” because the antibody will react with all panel cells, since all panel cells are Jk(a+b−), Jk(a−b+), or Jk(a+b+). The autocontrol tube may be either positive or negative depending on whether or not the patient has been recently transfused. The DAT will usually be positive for both anti-IgG and anti-C3. If the patient has been recently transfused (within the last 3 months), the use of allogeneic cells for adsorption procedures is necessary to rule out antibodies to other major blood group antigens. The decision to perform an elution rests with a facility’s protocol(s). Some facilities may elect to do an elution on any patient specimen with positive DAT results, whereas other facilities may be more selective in terms of number of days following a recent transfusion. The patient was questioned concerning transfusion of blood at other facilities and reported that he had never received a transfusion prior to the units that were given at Hospital B. The timing of this DHTR is consistent with the formation of a new antibody rather than an evanescent form.

Another laboratory test that can be helpful in the identification of the Jk(a−b−) phenotype is the urea lysis test. In 1982, Heaton and McLoughlin showed that Jk(a−b−) RBCs were resistant to lysis in the presence of 2M urea. RBCs with normal Kidd phenotypes rapidly swell and will lyse in the presence of 2M urea. In 1995, another group showed that the Kidd blood group antigens and urea transport function were carried on the same protein structure. As a result, individuals with the Jk(a−b−) phenotype may not be able to concentrate urine as well as individuals with normal Kidd antigens.

Serologic phenotyping is most commonly used to identify specific antigens on RBCs. A patient with the Jk(a−b−) phenotype should be nonreactive when tested with anti-Jk^a and anti-Jk^b typing sera. It is important to check the patient’s transfusion history, since recent transfusion could invalidate phenotyping results. If the patient has been recently transfused, autologous neocytes prepared through microhematocrit centrifugation can be used for phenotyping. Genotyping for Kidd variants may also be used to support serologic typing and to predict Kidd phenotypes when antisera are unavailable. This particular patient was shown to have inherited two variant alleles producing the Jk(a−b−) phenotype. Jk(a−b−) RBCs are recommended for transfusion in patients with anti-Jk3. Because of the rareness of the Jk(a−b−) phenotype, it is difficult to find blood for these patients. Finding compatible units for such patients will require the use of rare donor registries. Siblings of the patient can also be tested to see if they might be of the same phenotype as the patient.

In this case, IVIG was given to the patient because of the suspected parvovirus infection. This is one of the off-label uses of IVIG as described by Hillyer et al. Also, because IVIG is prepared from pools of donor plasma, it may contain antibodies to blood group antigens (e.g., anti-A, -B, -D, and -K; panagglutinins). In this particular case, the IVIG did not interfere in the serologic testing used to identify the antibody present in the patient’s serum.

This case report presents the findings of an extremely rare but clinically significant antibody. Anti-Jk3 is capable of causing severe DHTRs and HDFN. This antibody is difficult to identify in that it will present as a “panagglutinin,” meaning that it will react with all panel cells tested, since they are typically either Jk(a+) or Jk(b+) or both. The autocontrol may be positive if the patient has been recently transfused. If the autocontrol is positive, a DAT should be performed to characterize the protein coating the patient’s RBCs. An elution should also be performed to identify the antibody coating the patient’s RBCs, since it is not safe to assume that the antibody present in the patient’s serum is the same antibody that is coating the patient’s RBCs. Because most blood banks and transfusion services have limited resources, confirmation of the antibody specificity and phenotyping of the patient’s RBCs may need to be performed by a reference laboratory. Only blood that is Jk(a−b−) should be transfused to patients with anti-Jk3. Because of the difficulty in finding compatible units for such patients, rare donor registries will need to be consulted in the event that transfusion is required. The use of IVIG for patient treatment must be taken into consideration when performing serologic workup for suspected transfusion reactions because of contaminating antibodies that may be present in the formulation that could interfere with serologic testing.

**Acknowledgments**

Shaina McCaskill would like to thank Ronald Hansen, CLS, MT, Senior Medical Technologist, Blood Bank at Georgia Regents University, and Roni Bollag, MD, PhD, Medical Director of Blood Bank and Transfusion Medicine at Georgia...
Regents University, for assisting with the procurement of necessary patient test results and documentation for this case report.

References


Shaina McCaskill, MHS-CLS Candidate, Georgia Regents University; Scott Wise, MHA, CLS, MT, SBB, (corresponding author), Associate Professor; Georgia Regents University, 987 St. Sebastian Way, EC-2410, Augusta, GA 30912, swise@gru.edu; Sheila Tinsley, CLS, MT, SBB, Blood Bank Manager, Georgia Regents University, Augusta, GA 30912.

Manuscripts

The editorial staff of Immunohematology welcomes manuscripts pertaining to blood group serology and education for consideration for publication. We are especially interested in case reports, papers on platelet and white cell serology, scientific articles covering original investigations, and papers on new methods for use in the blood bank. For instructions for scientific articles, case reports, and review articles, see Instructions for Authors in every issue of Immunohematology or e-mail a request to immuno@redcross.org. Include fax and phone numbers and e-mail address with all manuscripts and correspondence. E-mail all manuscripts to immuno@redcross.org

Free Classified Ads and Announcements

Immunohematology will publish classified ads and announcements (SBB schools, meetings, symposia, etc.) without charge.

E-mail information to immuno@redcross.org or fax to (215) 451-2538
Severe hemolytic disease of the fetus and newborn due to anti-C+G


Anti-G is commonly present with anti-D and/or anti-C and can confuse serological investigations. In general, anti-G is not considered a likely cause of severe hemolytic disease of the fetus and newborn (HDFN), but it is important to differentiate it from anti-D in women who should be administered anti-D immunoglobulin prophylaxis. We report one woman with three pregnancies severely affected by anti-C+G requiring intrauterine treatment and a review of the literature. In our case, the identification of the correct antibody was delayed because the differentiation of anti-C+G and anti-D+C was not considered important during pregnancy since the father was D−. In addition, anti-C+G and anti-G titer levels were not found to be as reliable as is generally considered in Rh immunization. Severe HDFN occurred at a maternal anti-C+G antibody titer of 8 and anti-G titer of 1 in comparison with the critical titer level of 16 or more in our laboratory. Close collaboration between the immunohematology laboratory and the obstetric unit is essential. In previously affected families, early assessment for fetal anemia is required even when titers are low. Immunohematology 2015;31:123–127.

Key Words: anti-G, anti-C, HDFN, alloimmunization, intrauterine transfusion

Anti-D is the most common antibody responsible for severe hemolytic disease of the fetus and newborn (HDFN), but antibodies against other antigens belonging to the Rh blood group system can also cause HDFN. G, first described by Allen and Tippett,1 is part of the Rh blood group system and is dependent on expression of both the RHCE*Ce and RHD alleles. There are some exceptions, but most individuals who do not carry an RHD or RHCE*Ce allele would be expected to be negative for G. Anti-G often presents with anti-D and/or anti-C, but seldom alone. Anti-G should be suspected in cases where the anti-C titer is higher than the anti-D titer and confirmed by additional tests.2,3 Anti-G is present in approximately 30 percent of cases with apparent anti-D+C.4

Anti-G has been associated with HDFN. A few cases have been reported where anti-G was the probable cause of severe HDFN, but usually the disease is mild and does not require therapeutic intervention in the offspring.3,4,9 A case initially considered anti-D+C may turn out to be anti-C+G instead, and in these cases, anti-D prophylaxis should be administered to prevent anti-D alloimmunization and manifestation of HDFN in subsequent pregnancies.

In this case report, we describe the outcomes of three pregnancies of a Caucasian woman and her African husband, where anti-C+G caused severe HDFN requiring intrauterine (IU) transfusions.

Case Report

The patient had a history of two miscarriages and one extrauterine pregnancy. Subsequently, she had a normal pregnancy, where antenatal antibody screening was negative. In the following pregnancies, alloimmunization was identified, resulting in three cases of severe HDFN. In this case report, we present these affected pregnancies, designated as the first, second, and third (Table 1). According to the national protocol for antenatal antibody screening, maternal sampling began at 8–12 weeks of gestation in all pregnancies. The postnatal blood samples were drawn on the day of delivery.

In her first affected pregnancy (in 2009), the antibody screening was positive for what were at the time assumed to be anti-D and anti-C. Followed monthly, the antibody titers remained at moderate levels (4–8) until 34 weeks of gestation. Because the titer level was below the critical level of 16, ultrasound examinations to detect fetal anemia were not considered necessary. At 37 weeks of gestation, an emergency caesarean section was performed because of reduced fetal movements and a sinusoidal heart rate pattern in cardiotocography. A D− boy was delivered with a hemoglobin (Hb) of 3.1 g/dL and a positive direct antiglobulin test (DAT). Unexpectedly, the anti-D+C titer on a sample taken 5 days prior to the delivery and available postnatally was 128. Immediately postnataally, the anti-D+C titer was 64. The anti-C titer was higher than the anti-D titer, as had been the case already during the pregnancy, thus prompting suspicion of anti-G instead of anti-D. The infant recovered well after successful treatment with red blood cell (RBC) transfusion and treatment with intravenous immunoglobulin (IVIG).

At the beginning of her second affected pregnancy (in 2012), anti-D–like antibody, anti-C, and anti-Jkα were...
identified. The anti-D+C titer was 16 and the anti-Jk\textsuperscript{a} titer was 1. The antibody levels were followed monthly/fortnightly, and they remained unchanged during the pregnancy. Because the father was D–C+, at 16+2 weeks of gestation the fetus was genotyped from amniotic fluid sampling and found positive for a RHD-CE-D hybrid gene that is predicted to express no D and instead expresses an altered C. The fetus was then carefully monitored noninvasively with ultrasound examinations. No evidence of fetal anemia was apparent until 23 weeks of gestation, when the peak systolic velocity (PSV) in the middle cerebral artery (MCA) Doppler examinations exceeded 1.5 multiples of median (MoM). In cordocentesis at 24+1 weeks, the fetal Hb was 7.4 g/dL. A total of five IU transfusions were performed successfully between 24 and 34 weeks of gestation. Vaginal delivery was induced at 34 weeks and a slightly premature but otherwise healthy girl was born with a Hb of 14.1 g/dL and a negative DAT. Neonatal treatment included IVIG, phototherapy, and two top-up transfusions. Anti-C+G was confirmed postnatally.

At the beginning of her third affected pregnancy, in 2013, anti-C, anti-G, and anti-Jk\textsuperscript{a} were identified. During the pregnancy, the titers remained stable: 8–16 for anti-C+G, 2 for anti-G, and 1 for anti-Jk\textsuperscript{a}. The fetus was genotyped from amniotic cells as a RHD-CE-D hybrid at 21+1 weeks of gestation. Weekly ultrasound examinations were begun at 22+6 weeks. Middle cerebral artery PSV stayed under 1.29 MoM until 30+0 weeks, when it reached 1.4 MoM. Given the mother’s history, the last finding gave reason to suspect anemia, and the first IU transfusion was then scheduled. The Hb at the first transfusion was 8.8 g/dL. A total of three IU transfusions were performed between 31 and 35 weeks of gestation. Labor was induced at 36+0 weeks, and a healthy girl was born with a Hb of 14 g/dL and a negative DAT. Neonatal treatment included IVIG, phototherapy, and two top-up transfusions. Anti-C+G was confirmed postnatally.

### Table 1. The courses and outcomes of three pregnancies (in the years 2009, 2012, and 2013) of an alloimmunized D–C–c+E–e+Jk(a–b+) mother

<table>
<thead>
<tr>
<th>2009</th>
<th>2012</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibody</strong></td>
<td><strong>Titer</strong></td>
<td><strong>Titer cells</strong></td>
</tr>
<tr>
<td>Prenatal work-up</td>
<td>Anti-D+C</td>
<td>4–8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anti-Jk\textsuperscript{a}</td>
<td>1</td>
</tr>
<tr>
<td>Follow-up</td>
<td>Monthly antibody levels</td>
<td>Monthly antibody levels</td>
</tr>
<tr>
<td>Intervention</td>
<td>Emergency CS at 37 weeks (reduced fetal movements, sinusoid cardiotocography)</td>
<td>IU × 5, Hb (between 24 and 34 weeks), induction of labor at 34 weeks</td>
</tr>
<tr>
<td>Delivery</td>
<td>D– boy, DAT+ Hb 3.1 g/dL</td>
<td>D– girl, DAT– Hb 14.1 g/dL</td>
</tr>
<tr>
<td>Postnatal work-up</td>
<td>Anti-D+C\textsuperscript{*}</td>
<td>128</td>
</tr>
<tr>
<td></td>
<td></td>
<td>64–128</td>
</tr>
<tr>
<td></td>
<td>Anti-D+C\textsuperscript{a}</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td></td>
<td>128</td>
</tr>
<tr>
<td></td>
<td>Anti-C+G\textsuperscript{a}</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anti-Jk\textsuperscript{a} detected</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>IVIG, red cell transfusion</td>
<td>IVIG, phototherapy, red cell transfusion ×2</td>
</tr>
</tbody>
</table>

\textsuperscript{*}Sample taken 5 days prior to the delivery; result available 1 day postpartum.
\textsuperscript{a}Sample taken on the day of delivery.
\textsuperscript{b}Anti-C+G confirmed postnatally.
\textsuperscript{c}Sample taken from umbilical cord.

MCA = middle cerebral artery; PSV = peak systolic velocity, cm/sec; MoM = multiples of median; CS = caesarean section; IU = intrauterine; Hb = hemoglobin; DAT = direct antiglobulin test; IVIG = intravenous immunoglobulin.
boy was born with a Hb of 14 g/dL and a positive DAT. The child received IVIG treatment (× 3) and phototherapy, with the latter continued at home after discharge from the hospital.

Materials and Methods

All blood samples and amniotic fluid samples were analyzed in the Finnish Red Cross Blood Service (in Helsinki), which is a national reference laboratory to which the antenatal screening for RBC antibodies is centralized. In the second affected pregnancy, in 2012, a blood sample was also sent to the International Blood Group Reference Laboratory (IBGRL) in Bristol, UK, where absorption studies were performed to differentiate anti-G from anti-D and anti-C.

ABO and D typing of RBC samples from the mother were performed with an analyzer (PK7300, Olympus Corporation, Tokyo, Japan) on microtiter plates.

Antibody screening, identification, and DAT studies were carried out with a gel-based analyzer (DiaMed ID GelStation, DiaMed, Cressier, Switzerland). Antibody screening and identification were performed using a gel method (LISS/Coombs cards, Bio-Rad, Cressier, Switzerland) for untreated RBCs. Antibody identification with enzyme (papain)-treated RBCs in a gel method (NaCl card, DiaMed) was also used. A DAT was performed on the infant’s cord blood sample using polyspecific antihuman globulin (AHG) (anti-IgG and anti-C3D, Bio-Rad) in a gel method (LISS/Coombs cards). Serologic phenotyping was carried out with specific reagent gel cards (Bio-Rad).

Titrations were performed using the tube method for indirect antiglobulin test and R,r reagent RBCs for anti-D, anti-D+C, and anti-C; r,r for anti-C; and R,r for anti-G (because reagent cells with only C or G antigen were not available for routine use). During the first affected pregnancy, only R,r cells were used in titration of anti-D+C, but after delivery of the severely anemic D− child, titration was also performed with r,r cells. In the second affected pregnancy, cells used for titrating anti-D+C, anti-C, and anti-G were R,r, r,r, and R,r, respectively, throughout the pregnancy. In the third affected pregnancy, the titer cells used were R,r for anti-C+G and R,r for anti-G throughout the pregnancy. Titration for anti-Jk^a was performed with rr Jk(a+b+) reagent RBCs.

Genotyping of the fetal RHD and RHCE genes was carried out from amniotic cells using polymerase chain reaction with sequence specific primers (PCR-SSP) (PCR-SSP, Innotech, Kronberg, Germany) according to the manufacturer’s instructions.

Results

The Caucasian mother was phenotyped as D−C−c+E−e+; Jk(a−b+) and the African father as D−C+c+E−e+; Jk(a+b−). The father carried the RHD-CE-D hybrid, which encodes an altered C that reacts more weakly than a conventional C when using serologic methods. The father was the same in all pregnancies.

In the first affected pregnancy, the anti-D+C titer remained 4–8 using D+C+ (R,r) cells followed monthly. The titer was 128 using D−C+ (r′r) cells on a sample taken 5 days prior to the delivery and 64 immediately postnatally.

In the second affected pregnancy, the anti-D+C titer was 16 using D+C+ (R,r) and D−C+ (r′r) cells, and 2 with D+C− (R,r) cells.

A maternal blood sample had also been sent to the IBGRL in Bristol, UK, where anti-C+G and anti-Jk^a were confirmed and anti-D ruled out. The postpartum maternal anti-C+G titer was 8, and anti-G and anti-Jk^a titers were both 1; the anti-C+G titer from cord blood was 4 and anti-G titer was 1; anti-Jk^a was not detected.

During the third affected pregnancy, the antibody titers remained stable: 8–16 for anti-C+G using D+C+ (R,r) cells, 2 for anti-G using D+C− (R,r) cells, and 1 for anti-Jk^a. The postpartum maternal anti-C+G and anti-G titers were 4 and 2, respectively; anti-Jk^a titer was 1 and not obtained for analysis from the cord blood sample.

Discussion

In our patient, anti-C was the dominant antibody in all affected pregnancies, including the first, as could be confirmed retrospectively. The finding of a stronger anti-C compared with anti-D led to the suspicion of anti-G. In the first affected pregnancy, antibody levels remained low until a rapid increase in the final weeks before term, resulting in signs of fetal distress and an emergency caesarean section of a severely anemic child. The last titer level 3 weeks earlier was 8 but had risen to 128 by the time of delivery. In the following pregnancies, despite the fact that the antibody titers remained at moderate levels (2–16), IU transfusions were required.

Though there are several case reports in the literature of HDFN caused by anti-G/anti-C+G to our knowledge, only one of them required IU transfusion: a mother with a history of several affected pregnancies presented with severe HDFN caused by anti-C+G in a twin pregnancy. Maternal IVIG and plasmapheresis were required before IU RBC transfusions could be initiated, and despite intensive monitoring, one twin...
was lost and the other needed prolonged treatment including phototherapy, RBC transfusions, and erythropoietin injections. In a case report by Hadley et al., anti-G was found to be the cause of severe HDFN; cordocentesis was planned but found impossible to perform, and after delivery, the infant required several exchange transfusions. The third reported severe case of HDFN with anti-C+G was described by Jakobowicz and Simmons. Thus, anti-G can be clinically significant in pregnancy and may contribute to the development of moderate or severe HDFN, although most reported cases have been mild. For example, Muller et al. reported a typical case where anti-C+G was mistaken for anti-D+C in a primigravida who had received RBC transfusions prior to her pregnancy. After delivery of a D− baby, anti-C+G was identified in maternal blood by adsorption and elution, but no anti-D was detected. Lenkiewicz and Zupanska reported a pregnancy where anti-C+G antibodies were responsible for moderate hemolytic disease of the newborn, and, based on titration results, anti-G levels were much higher than anti-C.

Anti-G is only rarely the single antibody responsible for HDFN, but is more often expressed with anti-D, anti-C, or both. Palfi and Gunnarsson analyzed the D/C/G antibody combinations in 27 pregnancies and found that anti-G was present in 24 cases, and in 4 of the 27 cases, anti-C+G was identified without anti-D; anti-G was not found alone in any of these cases. Interestingly, Huber and coworkers reported a patient who did have anti-G as the sole cause of moderate hemolytic disease of the newborn—anti-D and anti-C were excluded.

In our case, the affected fetuses had inherited the hybrid allele RHD-CE-D from their father. The allele codes a D− and weak C+ phenotype. G is intact. Thus, both anti-C and anti-G could find the target antigens on the RBCs of the fetuses.

Furthermore, our case demonstrates that anti-C or anti-G titers are poor predictors of the outcome in an immunized pregnancy. In our facility, monitoring of pregnancies at high risk for HDFN is planned in collaboration with the immunohematology laboratory and the obstetric unit. Antibody screening, identification, and follow-up of antibody levels are carried out monthly or every 2 weeks. Usually, if critical antibody titer levels of 16 are reached, fetal ultrasound examinations begin at 18 weeks of gestation and continue weekly/fortnightly throughout the pregnancy. Fetal well-being is evaluated with serial ultrasound for signs of hydrops and Doppler measurement of the PSV of the MCA form the basis for follow-up in immunized pregnancies. In anemic fetuses, lower blood viscosity and increased cardiac output result in a higher PSV; a threshold value of 1.5 MoM is predictive of moderate to severe anemia, whereas levels lower than 1.29 are considered normal. This noninvasive method has replaced the need for assessment of amniotic bilirubin levels. Moreover, fetal RHD and RHCE genotyping from maternal serum is now feasible, although blood groups other than Rh still need to be analyzed from amniocytes.

Appropriate titer cells are important in the estimation of the role of anti-G. A significant number of cases where apparent anti-D+C are identified may actually contain only anti-C+G and lack anti-D. Anti-G should be considered if anti-C titer levels exceed or reach the levels of anti-D titers. In our case, cells used in titration were R,r for anti-D+C, R,r for anti-D and anti-G, and r,r for anti-C. The titer levels obtained with R,r cells were consistently higher than with R,r in all three pregnancies, indicating anti-C as the stronger antibody. In general, in our laboratory, when anti-D+C are identified, only R,r cells are used in titration. Anti-G should be suspected prior to titration if the antibody identification panel shows stronger reactions for anti-C than anti-D. Then, if titrations performed with R,r, R,r, and/or r,r cells also indicate the possibility of anti-G, additional tests should be carried out. In our laboratory, anti-G is demonstrated and anti-D ruled out with absorption studies performed concurrently with D−C+ and D+C− reagent RBCs. In many laboratories, differential absorption and elution is the method of choice, and is recommended for the differentiation of anti-G from anti-D. Furthermore, rare r,r cells may also be used in titration. National and international blood group reference laboratories may be of use in cases where antibody identification by in-house methods is challenging.

Identifying anti-G in serum that initially seems to contain anti-D+C is important because D− women shown to have anti-C+G but not anti-D should receive anti-D immunoglobulin prophylaxis when carrying or having delivered a D+ child. Failure to recognize these cases endangers future pregnancies, since alloimmunization may develop. Furthermore, if the father is D−, the identification of anti-C+G should be discussed, because an incorrect report of anti-D+C may lead to unnecessary distress, paternity testing, and social consequences. The number of reported anti-G cases is still low. Nevertheless, anti-G is more common than has traditionally been thought, and may contribute to the development of severe HDFN.

In conclusion, if a pregnant woman seems to have anti-D and anti-C, with anti-C being the stronger antibody, it is important to test for anti-G. Primarily, if anti-D can be excluded, the woman requires anti-D prophylaxis. In addition, anti-G can, especially in combination with anti-C, cause severe HDFN, even with low titer levels.
References


Riina Jernman, MD, PhD (corresponding author), Specialist in Obstetrics and Gynecology, Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, P.O. Box 140, 00029 HUS, Helsinki, Finland, riina.jernman@hus.fi; Vedran Stefanovic, MD, PhD, Specialist in Obstetrics and Gynecology, Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Anu Korhonen, MSc, Laboratory Specialist; Katri Haimila, PhD, Laboratory Specialist; Inna Sareneva, MSc, Laboratory Specialist; Kati Sulin, MSc, Laboratory Specialist; Malla Kuosmanen, Phil, Biologist; Susanna Sainio, MD, PhD, Specialist in Obstetrics and Gynecology, Finnish Red Cross Blood Service, Helsinki, Finland.
To the Editor

CD177/NB1 receptor expression is dynamically regulated in sepsis patients

Human neutrophils are central to the defense against invading microbes. Neutrophils are not homogenous, but exist in subgroups such as low-density neutrophils or subsets with differential olfactomedin-4 and CD177 expression.1 CD177 is a neutrophil-specific glycoprotein that is expressed intracellularly and on the neutrophil membrane in 95 percent of all individuals—3 to 5 percent of persons are CD177-deficient. In the former, the expression pattern is bimodal with distinct CD177-positive and CD177-negative subsets. The positive subset ranges from 0 to 100 percent, but remains stable in a given individual. Clinically, CD177 is relevant to anti-neutrophil cytoplasmic antibodies vasculitis,2 neutropenia in newborns, graft failure in bone marrow recipients, drug-induced neutropenia, and transfusion-related lung injury.3 A role for CD177 in neutrophil migration was suggested by engaging platelet-endothelial-cell-adhesion molecule-1 on endothelium.4

Mechanisms controlling the size of the CD177-positive neutrophil subset are unknown. To test whether or not the percentage of CD177-positive neutrophils changes during inflammation, we performed serial CD177 expression studies in a large patient cohort with acute bacterial sepsis and analyzed the data in relation to disease severity. Peripheral blood was obtained after local ethics board approval (EA1/144/10) from 96 patients in the intensive care unit with acute bacterial sepsis (Sequential Organ Failure score 10.0 ± 4.8). We included 33 disease controls with non-infectious systemic inflammatory response syndrome (solid organ transplantation, acute ischemic stroke, myocardial infarction) and 103 normal controls, respectively. The proportion of CD177-positive neutrophils and the mean fluorescence intensity (MFI) were determined by flow cytometry (PE anti-CD177 [clone:MEM-166], Biolegend, San Diego, CA). Fifty-six sepsis patients died, 36 before the scheduled 28-day follow-up flow cytometry assessment.

We found that sepsis patients, but not disease controls, displayed a significantly higher percentage of CD177-positive neutrophils and higher CD177 MFI at the initial assessment, compared with normal persons (Fig. 1A–C). Furthermore, the CD177-positive percentage and MFI changed concordant with clinical outcome. Both CD177-positive percentage and MFI decreased significantly in the 34 patients with inflammation resolution (Fig. 1D, E). C-reactive protein (CRP) decreased in these patients from 21.8 to 3.5 mg/dL and leukocytes from 11.8 to 8.6 × 10⁹/L. In contrast, both CD177 parameters remained elevated in the 26 patients who lacked clinical improvement (CRP from 23.1 to 20.2 mg/dL and leukocytes from 15.8 to 14.2 × 10⁹/L; Fig. 1C, D). One particularly informative patient was admitted with non-infectious systemic inflammatory response syndrome after myocardial infarction and developed Klebsiella pneumoniae pneumonia at day 6 and subsequent sepsis at day 17. CD177-positive neutrophil percentage and MFI increased from 52 percent/39MFI to 74 percent/80MFI at day 6 and finally to 83 percent/109MFI at day 17. The patient recovered, and, at day 39, the values had decreased to 58 percent/44MFI.

Taken together, our data indicate that a high percentage of CD177-positive neutrophils undergo dynamic changes during severe bacterial sepsis and that these changes affect clinical outcome. Possibly, the cytokine milieu modulates CD177 expression. Consistent with this assumption, extended, but not short-term, granulocyte-colony stimulating factor administration in healthy patients increased the CD177-positive neutrophil percentage.5 Further studies should be done to identify the exact mechanisms that control CD177 expression.

Adrian Schreiber, MD (corresponding author), adrian.schreiber@charite.de
Alexandra Jennerjahn, MD
Ralph Kettritz, MD, Professor

Experimental and Clinical Research Center, a joint cooperation between the Charité and the Max-Delbrück Center for Molecular Medicine, Nephrology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Virchow, Berlin, Lindenberger Weg 80, 13125 Berlin, Germany
Fig. 1. CD177 expression in sepsis patients, disease controls, and normal persons. The percentage of CD177-positive neutrophils per study group is shown as number of patient per decile (A). The percentage of CD177-positive neutrophils (B) and the mean CD177 expression (C) are significantly higher in sepsis patients compared with normal and disease controls (DC). The percentage of CD177-positive neutrophils (D) and the mean CD177 expression (E) decreased with clinical improvement (improvement), but not in sepsis patients without improvement (no improvement). Normal controls (NC) are shown for comparison. **p < 0.01. MFI = mean fluorescence intensity; ns = no signal.

References


To the Editor

Alternative to providing ABO-incompatible donors for patients in end-stage renal disease: renal transplant registries, the need of the hour

Transplantation antigens can be classified into major histocompatibility antigens, ABO and Rh blood group antigens, and minor histocompatibility antigens. ABO compatibility—generally not considered critical in hematopoietic cell (HPC) transplants because pluripotent and early committed HPCs do not express ABO antigens—is, however, an important consideration in solid organ transplants. Removal of patient anti-A and/or -B that would be incompatible with the transplant is usually achieved by therapeutic plasma exchanges (TPEs) or by immunoadsorption, which specifically removes anti-A and/or -B by affinity column. We report a case of a nonproductive major ABO incompatible (ABO-I) renal transplant (included in category I for American Society for Apheresis guidelines for apheresis) in a patient started on TPEs and immunosuppressive regimen to lower the titer of incompatible antibody.

A 36-year-old male patient, with a known history of type II diabetes mellitus for 16 years, was diagnosed with chronic renal failure progressing to end-stage renal disease (ESRD). His blood group was O, D+. He had a family history of diabetes mellitus (in his mother and younger sister) as well as diabetic retinopathy and diabetic neuropathy. He was currently on insulin therapy. The patient had a history of oliguria for a year and was being maintained on hemodialysis. On investigation, he was found to have anemia and azotemia: serum urea = 112 mg% (normal range: 10–50 mg%); creatinine = 5.68 mg% (normal range: 0.8–1.8 mg%). The patient had planned to receive a renal transplant from his brother (not a known diabetic) who typed as group O, D+. However, his brother refused to donate. Subsequently, his wife, who types as group B, D+, was worked up as a donor. Because the baseline anti-B titers in the patient’s serum against pooled reagent B cells were 8 (IgM) and 512 (IgG), he was prepared for desensitization to the ABO-I renal transplant. TPEs (centrifugal TPE on Cobe Spectra cell separator) were planned for the patient to reduce the anti-B titer. Simultaneously, he was put on an immunosuppressive regimen 2 weeks before the transplant that included rituximab (375 mg/m²) single dose, intravenous immunoglobulin (IVIG 100 mg/kg), tacrolimus (4 g/day), and mycophenolate mofetil (2 g/day). A total of 15 TPEs were performed; 11 were performed every alternate day and 4 were performed at 2-day intervals. The procedures involved exchanging 1 to 1.5 times the patient’s plasma volume with group B, D+, fresh-frozen plasmas (FFPs) that were screened by enzyme-linked immunosorbent assay (ELISA) and nucleic acid testing (NAT) for transfusion transmitted infection (TTI). The units of FFP were purposely group specific (B) to gain the added advantage of antibody neutralization by the soluble B antigenic substance in plasma. The patient did not experience any major complications during the procedures. Anti-B titers were repeated after every TPE procedure. Figure 1 shows the anti-B titers (IgG) at antihuman globulin (AHG) phase with respect to each TPE. Anti-B titers after the 15th TPE procedure were 2 (IgM) and 128 (IgG), respectively. After this, no further procedures were performed, and the renal transplant was not performed.

Renal transplant is the treatment of choice in ESRD. It is difficult to maintain the patient on long-term dialysis. Because ABO antigens are present on the surface of the endothelium of vessels and basement membranes of renal tubular cells, they constitute a strong histocompatibility barrier for renal transplants. Major incompatibility refers to the presence of preexisting natural antibodies in the recipient against the donor’s A and/or B blood group antigens, which can lead to hyperacute/acute humoral rejection of the organ because of endothelial damage. Minor incompatibility occurs when the organ donor has naturally occurring ABO antibodies against the recipient, which can cause passenger lymphocyte syndrome.

Limitations in donor availability for stem cell or organ transplantation require that ABO-I donors be used. Although ABO-I transplantation entails increased expense when compared with maintenance dialysis, the benefits of a successful transplant and the subsequent health-related quality of life make it clearly cost-effective. For ABO-I renal transplantation to be effective, pre-existing patient antibodies directed at antigen(s) on the donor organ must be minimized. The goal is to bring the recipient to a titer below a set target and prevent production of additional ABO antibodies before and after transplantation. The most significant
Need for renal transplant registries
developments in ABO-I, solid organ transplantation with immediate clinical applicability and impact are the use of TPEs and immunoadsorption protocols to reduce recipient isoagglutinin levels before and after transplantation.²

Various pre-conditioning protocols are used in different combinations to reduce the titer of circulating ABO antibody (IgG) to less than or equal to 16, permitting engraftment of ABO-I kidney transplants.² TPE along with immunosuppressive regimens is the most commonly used method worldwide. TPE is a nonselective procedure, since it removes not only ABO antibodies but nonspecific antibodies as well. Selective methods such as double filtration plasmapheresis and antigen-specific immunoadsorption using immunoabsorption columns (Glycosorb-ABO columns, Glycorex Transplantation, Lund, Sweden) are available at few centers in India.

Our patient who typed as group O, D+, planned for renal transplant using a live renal donor who typed B, D+. Because of the major ABO incompatibility, the patient was started on a TPE and immunosuppressive regimen. The baseline anti-B titer (IgG) was high (512). Transplantation was to be performed when the anti-B titer reached 4. However, this could not be achieved.

In a retrospective study that included 46 individuals who had ABO-I renal transplants, it was seen that patients with higher initial antibody levels or rebounding titers between treatments received more TPEs.² In a study from Johns Hopkins, a protocol was proposed for the required number of pre- and post-transplant TPE procedures based on pre-TPE ABO IgG antibody titers. The authors observed that patients with higher pre-TPE ABO titers had to undergo more therapeutic procedures to remove the antibody.³ Lawrence et al. undertook a prospective study on 56 patients awaiting ABO-I renal transplants to determine a
cutoff titer above which patients should not enter the ABO-I program, using the relationship between the starting ABO IgG titer and the number of TPEs required. They introduced a cutoff titer of 256 for baseline ABO antibody for consideration of ABO-I renal transplants. They emphasized that patients with higher titers should not be exposed to costly, prolonged courses of immunosuppression and TPE without the guarantee of successful transplantation. Despite these considerations, we decided to go ahead with the preparation protocol in our patient, since the renal failure was progressive and an ABO-compatible renal donor was not available.

For the first two TPE procedures, the titer was 512; the antibody titers then remained stable at 64, decreased to 32 after the seventh procedure, and returned to 64 through the tenth procedure. The lowest titer recorded was 8 after the 11th procedure, which was followed by a subsequent increase to 128 after the 15th procedure. Thereafter procedures were stopped.

There are few case reports in the literature with successful ABO-I renal transplant in patients with high-titer ABO antibodies. In a case report from India, a renal transplant was successfully performed in a patient who typed as group O, D−, who received an organ from his mother, who was group B, D+. The baseline anti-B titer was 512, and it decreased to 8 after 11 TPEs and immunosuppression. In a case report from Japan, successful ABO-I renal transplantation was performed in three patients with high (>512) ABO antibody titer using a preconditioning protocol consisting of rituximab infusions, splenectomy, plasmapheresis, and pharmacologic immunosuppression. It was the same scenario with our patient, with the only difference being that splenectomy was not performed in our case.

We conclude that in a patient whose ABO titer exceeds the cutoff and the trial of TPE fails to decrease the titer to the desired level, the patient should be counseled and offered alternative routes to transplantation. In patients with blood group O, renal transplants from A₂ blood group individuals are preferred as compared with other blood groups because of the low expression of A antigen on the graft. A novel approach of blood group antigen-neutralizing therapy has been introduced in which A and B blood group antigens on red blood cells and in kidney tissues are neutralized by blood group antigen–targeting peptide (BATP). In New Zealand, a kidney transplant chain has been developed to overcome such incompatibilities through recipients “exchanging” incompatible for compatible donors. A paired and pooled kidney scheme allows matching a potential kidney recipient having a willing but incompatible donor to another incompatible pair resulting in both recipients receiving a compatible kidney. List Donation involves exchange of a live donor kidney for a deceased donor kidney. Non-Directed Donors is a strategy to allocate donors who desire to donate a kidney but do not have a designated recipient.

Thus, the time is opportune to develop a national Kidney Paired Donation program in India with improved coordination among various transplant centers, since the use of unrelated living donors has great potential to increase the donor pool. Maintaining renal transplant donor registries that have a database of voluntary renal donors can greatly facilitate such a program.

Sheetal Malhotra, MD (corresponding author), sheetalpgi2007@yahoo.com, Department of Transfusion Medicine
Gian Sagar, Medical College and Hospital, Patiala, India 140601
Hari Krishan Dhawan, MD
Ratti Ram Sharma, MD
Neelam Marwaha, MD
Department of Transfusion Medicine, PGIMER, Chandigarh, India 160012
References


JOIN US JUNE 5 & 6
For the 2016 AIMS Program
In Houston, Texas

The Advanced Immunohematology and Molecular Symposium (AIMS) is targeted towards people passionate about Immunohematology and seeking continuing education in the fields of Immunohematology and/or reference laboratory work including molecular testing.

SCHOLARSHIP AVAILABLE!
The John Moulds Scholarship consists of a complimentary AIMS registration, two nights’ hotel accommodations and MORE!
Visit www.scabb.org > Education Events for complete details on applying for this scholarship.
Masters (MSc) in Transfusion and Transplantation Sciences at The University of Bristol, England

Applications are invited from medical or science graduates for the Master of Science (MSc) degree in Transfusion and Transplantation Sciences at the University of Bristol. The course starts in October 2016 and will last for 1 year. A part-time option lasting 2 or 3 years is also available. There may also be opportunities to continue studies for PhD or MD following the MSc. The syllabus is organized jointly by The Bristol Institute for Transfusion Sciences and the University of Bristol, Department of Pathology and Microbiology. It includes:

• Scientific principles of transfusion and transplantation
• Clinical applications of these principles
• Practical techniques in transfusion and transplantation
• Principles of study design and biostatistics
• An original research project

Application can also be made for Diploma in Transfusion and Transplantation Science or a Certificate in Transfusion and Transplantation Science.

The course is accredited by the Institute of Biomedical Sciences.

Further information can be obtained from the Web site: http://ibgrl.blood.co.uk/MSc/MscHome.htm

For further details and application forms please contact:

Dr Patricia Denning-Kendall
University of Bristol
Paul O’Gorman Lifeline Centre
Department of Pathology and Microbiology
Southmead Hospital
Westbury-on-Trym, Bristol BS10 5NB, England
Fax +44 1179 595 342, Telephone +44 1779 595 455, e-mail: p.a.denning-kendall@bristol.ac.uk.
Online Specialist in Blood Bank (SBB) Certificate and Masters in Clinical Laboratory Management Program
Rush University
College of Health Sciences

Continue to work and earn graduate credit while the Rush University SBB/MS program prepares you for the SBB exam and the Diplomat in Laboratory Management (DLM) exam given by ASCP Board of Certification! (Please note acceptable clinical experience is required for these exams.)

Rush University offers online graduate level courses to help you achieve your career goals. Several curricular options are available. The SBB/MS program at Rush University is currently accepting applications for Fall 2016. For additional information and requirements, please visit our website at: www.rushu.rush.edu/cls/

Rush University is fully accredited by the Higher Learning Commission (HLC) of the North Central Association of Colleges and Schools and the SBB Certificate Program is accredited by the Commission on Accreditation of Allied Health Education Programs (CAAHEP).

Applications for the SBB/MS Program can be submitted online at the following website: http://www.rushu.rush.edu/admiss/hlthadm.html

Contact: Yolanda Sanchez, MS, MLS(ASCP)℠SBB, Director, by email at Yolanda_Sanchez@rush.edu or by phone at 312-942-2402 or Denise Harmening, PhD, MT(ASCP), Director of Curriculum by email at Denise_Harmening@rush.edu
The Johns Hopkins Hospital Transfusion Medicine Division is one of the busiest in the country and can provide opportunities to perform tasks that represent the entire spectrum of Immunohematology and Transfusion Medicine practice. It provides comprehensive support to all routine and specialized areas of care for surgery, oncology, cardiac, obstetrics, neonatal and pediatric, solid organ and bone marrow transplant, therapeutic apheresis, and patients with hematological disorders to name a few. Our intradepartment Immunohematology Reference Laboratory provides resolution of complex serologic problems, transfusion management, platelet antibody, and molecular genotype testing.

The Johns Hopkins Hospital Specialist in Blood Bank Technology Program is an onsite work-study, graduate-level training program for certified Medical Technologists, Medical Laboratory Scientists, and Technologists in Blood Banking with at least two years of full-time Blood Bank experience.

The variety of patients, the size, and the general intellectual environment of the hospital provide excellent opportunities for training in Blood Banking. It is a challenging program that will prepare competent and knowledgeable graduates who will be able to effectively apply practical and theoretical skills in a variety of employment settings. The Johns Hopkins Hospital Specialist in Blood Bank Technology Program is accredited by the Commission on Accreditation of Allied Health Education Programs (CAAHEP). Please visit our website at http://pathology.jhu.edu/department/divisions/transfusion/sbb.cfm for additional information.

Contact: Lorraine N. Blagg, MA, MLS(ASCP)CMSBB
Program Director
E-mail: lblagg1@jhmi.edu
Phone: (410) 502-9584

The Johns Hopkins Hospital
Department of Pathology
Division of Transfusion Medicine
Sheikh Zayed Tower, Room 3100
1800 Orleans Street
Baltimore, Maryland 21287

Phone (410) 955-6580
Fax (410) 955-0618
Web site: http://pathology.jhu.edu/department/divisions/transfusion/index.cfm
A must for the bookshelf of every blood bank. A superb and beautiful book.

John Gorman MD, Lasker Award 1980

The authors convey the excitement of scientific discovery so effectively on every page.

S. Gerald Sandler, MD
Professor of Medicine and Pathology,
Georgetown University Hospital

It’s more like reading an eye-witness account than a scientific textbook. Wonderfully readable, and a great addition to the books on blood groups.

Phyllis Walker, MT(ASCP)SBB, San Francisco

A landmark book . . . Every MD and clinical transfusion service should have their own personal copy.

Sandra J. Nance

The most valued and useful resource in my blood banking and immunohematology library . . . it is highly readable and an enjoyable, painless way to update your information about blood group antigens.

Immunohematology

Blood Group Antigens & Antibodies
by Marion Reid & Christine Lomas-Francis
Paperback/5.4” x 8.4”/214 pp./$25.00
ISBN 978-1-59572-103-7

AVAILABLE NOW!
To order, call 718-784-9112
or visit www.bloodgroups.info
www.sbbpocketbook.com
What is a certified Specialist in Blood Banking (SBB)?
• Someone with educational and work experience qualifications who successfully passes the American Society for Clinical Pathology (ASCP) board of registry (BOR) examination for the Specialist in Blood Banking.
• This person will have advanced knowledge, skills, and abilities in the field of transfusion medicine and blood banking.

Individuals who have an SBB certification serve in many areas of transfusion medicine:
• Serve as regulatory, technical, procedural, and research advisors
• Perform and direct administrative functions
• Develop, validate, implement, and perform laboratory procedures
• Analyze quality issues preparing and implementing corrective actions to prevent and document issues
• Design and present educational programs
• Provide technical and scientific training in transfusion medicine
• Conduct research in transfusion medicine

Who are SBBs?
Supervisors of Transfusion Services  Managers of Blood Centers  LIS Coordinators  Educators
Supervisors of Reference Laboratories  Research Scientists  Consumer Safety Officers  Reference Lab Specialists
Quality Assurance Officers  Technical Representatives

Why become an SBB?
Professional growth  Job placement  Job satisfaction  Career advancement

How does one become an SBB?
• Attend a CAAHEP-accredited SBB Technology program OR
• Sit for the examination based on criteria established by ASCP for education and experience.

However: In recent years, a greater percentage of individuals who graduate from CAAHEP-accredited programs pass the SBB exam.

Conclusion: The BEST route for obtaining an SBB certification is . . . to attend a CAAHEP-accredited Specialist in Blood Bank Technology Program.

Additional information can be found by visiting the following Web sites: www.ascp.org, www.caahep.org, and www.aabb.org

Contact the following programs for more information:

<table>
<thead>
<tr>
<th>Program</th>
<th>Contact Name</th>
<th>Phone Contact</th>
<th>E-mail Contact</th>
<th>Web Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Systems Laboratories</td>
<td>Marie P. Holub</td>
<td>602-996-2396</td>
<td><a href="mailto:mholub@bloodsystemslab.org">mholub@bloodsystemslab.org</a></td>
<td><a href="http://www.bloodsystemslaboratories.org">www.bloodsystemslaboratories.org</a></td>
</tr>
<tr>
<td>Walter Reed Army Medical Center</td>
<td>William Turkcan</td>
<td>301-295-8605</td>
<td><a href="mailto:William.Turkan@med.navy.mil">William.Turkan@med.navy.mil</a></td>
<td><a href="http://www.militaryblood.dod.mil/Fellow/default.aspx">www.militaryblood.dod.mil/Fellow/default.aspx</a></td>
</tr>
<tr>
<td>American Red Cross, Southern California Region</td>
<td>Catherine Hernandez</td>
<td>909-858-7496</td>
<td><a href="mailto:Catherine.Hernandez@redcross.org">Catherine.Hernandez@redcross.org</a></td>
<td><a href="http://www.redcrossblood.org/local/communityeducation">www.redcrossblood.org/local/communityeducation</a></td>
</tr>
<tr>
<td>ARC-Central OH Region</td>
<td>Joanne Kosanke</td>
<td>614-253-2740 ext. 2270</td>
<td><a href="mailto:Joanne.Kosanke@redcross.org">Joanne.Kosanke@redcross.org</a></td>
<td>none</td>
</tr>
<tr>
<td>Blood Center of Wisconsin</td>
<td>Phyllis Kirchner</td>
<td>414-937-6271</td>
<td><a href="mailto:Phyllis.Kirchner@bcw.edu">Phyllis.Kirchner@bcw.edu</a></td>
<td><a href="http://www.bcw.edu">www.bcw.edu</a></td>
</tr>
<tr>
<td>Community Blood Center/CTS Dayton, Ohio</td>
<td>Nancy Lang</td>
<td>937-461-3293</td>
<td><a href="mailto:nlang@cbcts.org">nlang@cbcts.org</a></td>
<td><a href="http://www.cbcts.org/education/sbb.htm">www.cbcts.org/education/sbb.htm</a></td>
</tr>
<tr>
<td>Gulf Coast Regional Blood Center</td>
<td>Clare Wong</td>
<td>713-791-6201</td>
<td><a href="mailto:cwong@giveblood.org">cwong@giveblood.org</a></td>
<td><a href="http://www.giveblood.org/services/education/sbb-distance-program">www.giveblood.org/services/education/sbb-distance-program</a></td>
</tr>
<tr>
<td>Havworth Blood Center, University of Cincinnati Medical Center</td>
<td>Pamela Inglish</td>
<td>513-558-1275</td>
<td><a href="mailto:Inglishpf@ucmail.uc.edu">Inglishpf@ucmail.uc.edu</a></td>
<td><a href="http://www.grad.uc.edu">www.grad.uc.edu</a></td>
</tr>
<tr>
<td>Indiana Blood Center</td>
<td>Jayanna Stayton</td>
<td>317-916-5186</td>
<td><a href="mailto:jstayton@indianablood.org">jstayton@indianablood.org</a></td>
<td><a href="http://www.indianablood.org">www.indianablood.org</a></td>
</tr>
<tr>
<td>Johns Hopkins Hospital</td>
<td>Lorraine N. Blagg</td>
<td>410-502-9584</td>
<td><a href="mailto:lbagg@jhmi.edu">lbagg@jhmi.edu</a></td>
<td><a href="http://pathology.jhu.edu/department/divisions/transfusion/abb.cfm">http://pathology.jhu.edu/department/divisions/transfusion/abb.cfm</a></td>
</tr>
<tr>
<td>Medical Center of Louisiana</td>
<td>Karen Kirkley</td>
<td>504-903-3954</td>
<td><a href="mailto:kkirkley@lsuhsc.edu">kkirkley@lsuhsc.edu</a></td>
<td><a href="http://www.mdtno.org/webresources/index.html">www.mdtno.org/webresources/index.html</a></td>
</tr>
<tr>
<td>NIH Clinical Center Blood Bank</td>
<td>Karen Byrne</td>
<td>301-496-8335</td>
<td><a href="mailto:kbyrne@mail.cc.nih.gov">kbyrne@mail.cc.nih.gov</a></td>
<td><a href="http://www.cc.nih.gov/htm">www.cc.nih.gov/htm</a></td>
</tr>
<tr>
<td>Rush University</td>
<td>Yolanda Sanchez</td>
<td>312-942-2402</td>
<td><a href="mailto:Yolanda_Sanchez@rush.edu">Yolanda_Sanchez@rush.edu</a></td>
<td><a href="http://www.rushu.rush.edu/cls">www.rushu.rush.edu/cls</a></td>
</tr>
<tr>
<td>Transfusion Medicine Center at Florida Blood Services</td>
<td>Marjorie Day</td>
<td>727-568-5433 ext. 1514</td>
<td><a href="mailto:mdaley@flblood.org">mdaley@flblood.org</a></td>
<td><a href="http://www.flblood.org">www.flblood.org</a></td>
</tr>
<tr>
<td>Univ. of Texas Health Science Center at San Antonio</td>
<td>Linda Myers</td>
<td>210-731-5526</td>
<td><a href="mailto:lmyers@bloodtissue.org">lmyers@bloodtissue.org</a></td>
<td><a href="http://www.bloodtissue.org">www.bloodtissue.org</a></td>
</tr>
<tr>
<td>University of Texas Medical Branch at Galveston</td>
<td>Janet Vincent</td>
<td>409-772-3055</td>
<td><a href="mailto:jvincent@utmb.edu">jvincent@utmb.edu</a></td>
<td><a href="http://www.utmb.edu/abb">www.utmb.edu/abb</a></td>
</tr>
<tr>
<td>University of Texas SW Medical Center</td>
<td>Lesley Lee</td>
<td>214-649-1785</td>
<td><a href="mailto:lesley.lee@utsouthwestern.edu">lesley.lee@utsouthwestern.edu</a></td>
<td><a href="http://www.utsouthwestern.edu/education/school-of-health-professions/programs/certificate-programs/medical-laboratory-sciences/index.html">www.utsouthwestern.edu/education/school-of-health-professions/programs/certificate-programs/medical-laboratory-sciences/index.html</a></td>
</tr>
</tbody>
</table>

Revised February 2013
Diagnostic testing for:
- Neonatal alloimmune thrombocytopenia (NAIT)
- Posttransfusion purpura (PTP)
- Refractoriness to platelet transfusion
- Heparin-induced thrombocytopenia (HIT)
- Alloimmune idiopathic thrombocytopenia purpura (AITP)

Medical consultation available

Test methods:
- GTI systems tests
  - detection of glycoprotein-specific platelet antibodies
  - detection of heparin-induced antibodies (PF4 ELISA)
- Platelet suspension immunofluorescence test (PSIFT)
- Solid phase red cell adherence (SPRCA) assay
- Molecular analysis for HPA-1a/1b

For further information, contact:
Platelet Serology Laboratory (215) 451-4205
Sandra Nance (215) 451-4362
Sandra.Nance@redcross.org
American Red Cross Biomedical Services
Musser Blood Center
700 Spring Garden Street
Philadelphia, PA 19123-3594

National Reference Laboratory for Specialized Testing

National Neutrophil Serology Reference Laboratory

Our laboratory specializes in granulocyte antibody detection and granulocyte antigen typing.

Indications for granulocyte serology testing include:
- Alloimmune neonatal neutropenia (ANN)
- Autoimmune neutropenia (AIN)
- Transfusion-related acute lung injury (TRALI)

Methodologies employed:
- Granulocyte agglutination (GA)
- Granulocyte immunofluorescence by flow cytometry (GIF)
- Monoclonal antibody immobilization of neutrophil antigens (MAINA)

TRALI investigations also include:
- HLA (PRA) Class I and Class II antibody detection

For further information, contact:
Neutrophil Serology Laboratory (651) 291-6797
Randy Schuller (651) 291-6758
Randy.Schuller@redcross.org
American Red Cross Biomedical Services
Neutrophil Serology Laboratory
100 South Robert Street
St. Paul, MN 55107
**Antibody identification and problem resolution**

- HLA-A, B, C, and DR typing
- HLA-disease association typing
- Paternity testing/DNA

**For information, contact:**

Mehdizadeh Kashi  
(at (503) 280-0210)

or write to:

**Tissue Typing Laboratory**  
American Red Cross Biomedical Services

**Pacific Northwest Region**

3131 North Vancouver  
Portland, OR 97227

---

**IgA testing is available to do the following:**

- Identify IgA-deficient patients
- Investigate anaphylactic reactions
- Confirm IgA-deficient donors

Our ELISA for IgA detects protein to 0.05 mg/dL.

**For additional information contact:**

Sandra Nance (215) 451-4362  
or e-mail:  
Sandra.Nance@redcross.org

or write to:

**American Red Cross Biomedical Services**

**Musser Blood Center**

700 Spring Garden Street  
Philadelphia, PA 19123-3594

ATTN: Sandra Nance  
CLIA licensed

---

**Donor IgA Screening**

- Effective tool for screening large volumes of donors
- Gel diffusion test that has a 15-year proven track record:  
  Approximately 90 percent of all donors identified as IgA deficient by this method are confirmed by the more sensitive testing methods

**For additional information:**

Kathy Kaherl  
(at (860) 678-2764  
e-mail:  
Katherine.Kaherl@redcross.org

or write to:

**Reference Laboratory**

American Red Cross Biomedical Services  
Connecticut Region

209 Farmington Ave.  
Farmington, CT 06032

---

**Reference and Consultation Services**

**Immunohematology Reference Laboratory**  
AABB, ARC, New York State, and CLIA licensed

24-hour phone number:  
(215) 451-4990

Fax: (215) 451-2538

**American Rare Donor Program**

24-hour phone number:  
(215) 451-4900

Fax: (215) 451-2538

ardp@redcross.org

**Immunohematology**

Phone, business hours:  
(215) 451-4902

Fax: (215) 451-2538

immuno@redcross.org

**Quality Control of Cryoprecipitated–AHF**

Phone, business hours:  
(215) 451-4903

Fax: (215) 451-2538
A. For describing an allele which has not been described in a peer-reviewed publication and for which an allele name or provisional allele name has been assigned by the ISBT Working Party on Blood Group Allele Terminology (http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-blood-group-terminology/blood-group-terminology/blood-group-allele-terminology/)

B. Preparation
1. Title: Allele Name (Allele Detail)
   ex. RHCE*01.01 (RHCE*ce48C)
2. Author Names (initials and last name of each (no degrees, ALL CAPS)

C. Text
1. Case Report
   i. Clinical and immunohematologic data
   ii. Race/ethnicity and country of origin of proband, if known
2. Materials and Methods
   Description of appropriate controls, procedures, methods, equipment, reagents, etc. Equipment and reagents should be identified in parentheses by model or lot and manufacturer’s name, city, and state. Do not use patient names or hospital numbers.
3. Results
   Complete the Table Below:

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Allele Name</th>
<th>Nucleotide(s)</th>
<th>Exon(s)</th>
<th>Amino Acid(s)</th>
<th>Allele Detail</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>e weak</td>
<td>RHCE*01.01</td>
<td>48G&gt;C</td>
<td>1</td>
<td>Trp16Cys</td>
<td>RHCE*ce48C</td>
<td>1</td>
</tr>
</tbody>
</table>

Column 1: Describe the immunohematologic phenotype (ex. weak or negative for an antigen).
Column 2: List the allele name or provisional allele name.
Column 3: List the nucleotide number and the change, using the reference sequence (see ISBT Blood Group Allele Terminology Pages for reference sequence ID).
Column 4: List the exons where changes in nucleotide sequence were detected.
Column 5: List the amino acids that are predicted to be changed, using the three-letter amino acid code.
Column 6: List the non-consensus nucleotides after the gene name and asterisk.
Column 7: If this allele was described in a meeting abstract, please assign a reference number and list in the Reference section.

4. Additional Information
   i. Indicate whether the variant is listed in the dbSNP database (http://www.ncbi.nlm.nih.gov/snp/); if so, provide rs number and any population frequency information, if available.
   ii. Indicate whether the authors performed any population screening and if so, what the allele and genotype frequencies were.
   iii. Indicate whether the authors developed a genotyping assay to screen for this variant and if so, describe in detail here.
   iv. Indicate whether this variant was found associated with other variants already reported (ex. RHCE*ce48C, 1025T is often linked to RHD*DIVa-2)

D. Acknowledgments

E. References

F. Author Information
   List first name, middle initial, last name, highest degree, position held, institution and department, and complete address (including ZIP code) for all authors. List country when applicable.
I. GENERAL INSTRUCTIONS
Before submitting a manuscript, consult current issues of Immunohematology for style. Number the pages consecutively, beginning with the title page.

II. SCIENTIFIC ARTICLE, REVIEW, OR CASE REPORT WITH LITERATURE REVIEW
A. Each component of the manuscript must start on a new page in the following order:
   1. Title page
   2. Abstract
   3. Text
   4. Acknowledgments
   5. References
   6. Author information
   7. Tables
   8. Figures

B. Preparation of manuscript
   1. Title page
      a. Full title of manuscript with only first letter of first word capitalized (bold title)
      b. Initials and last name of each author (no degrees; all CAPS), e.g., M.T. JONES, J.H. BROWN, AND S.R. SMITH
      c. Running title of ≤ 40 characters, including spaces
      d. Three to ten key words
   2. Abstract
      a. One paragraph, no longer than 300 words
      b. Purpose, methods, findings, and conclusion of study
   3. Key words
   4. Text (serial pages): Most manuscripts can usually, but not necessarily, be divided into sections (as described below). Survey results and review papers may need individualized sections
      a. Introduction — Purpose and rationale for study, including pertinent background references
      b. Case Report (if indicated by study) — Clinical and/or hematologic data and background serology/molecular
      c. Materials and Methods — Selection and number of subjects, samples, items, etc. studied and description of appropriate controls, procedures, methods, equipment, reagents, etc. Equipment and reagents should be identified in parentheses by model or lot and manufacturer’s name, city, and state. Do not use patient’s names or hospital numbers.
      d. Results — Presentation of concise and sequential results, referring to pertinent tables and/or figures, if applicable
      e. Discussion — Implication and limitations of the study, links to other studies, if appropriate, link conclusions to purpose of study as stated in introduction
   5. Acknowledgments: Acknowledge those who have made substantial contributions to the study, including secretarial assistance; list any grants.
   6. References
      a. In text, use superscript, Arabic numbers.
      b. Number references consecutively in the order they occur in the text.
   7. Tables
      a. Head each with a brief title; capitalize the first letter of first word (e.g., Table 1. Results of…) use no punctuation at the end of the title.
   8. Figures
      a. Figures can be submitted either by e-mail or as photographs (5 ×7″ glossy).
      b. Place caption for a figure on a separate page (e.g. Fig. 1 Results of…), ending with a period. If figure is submitted as a glossy, place first author’s name and figure number on back of each glossy submitted.
      c. When plotting points on a figure, use the following symbols if possible:
         ● ○ ▲ △ ▽ ▼.
   9. Author information
      a. List first name, middle initial, last name, highest degree, position held, institution and department, and complete address (including ZIP code) for all authors. List country when applicable. Provide e-mail addresses of all authors.

III. EDUCATIONAL FORUM
A. All submitted manuscripts should be approximately 2000 to 2500 words with pertinent references. Submissions may include:
   1. An immunohematologic case that illustrates a sound investigative approach with clinical correlation, reflecting appropriate collaboration to sharpen problem solving skills
   2. Annotated conference proceedings

B. Preparation of manuscript
   1. Title page
      a. Capitalize first word of title.
      b. Initials and last name of each author (no degrees; all CAPS)
   2. Text
      a. Case should be written as progressive disclosure and may include the following headings, as appropriate
         i. Clinical Case Presentation: Clinical information and differential diagnosis
         ii. Immunohematologic Evaluation and Results: Serology and molecular testing
         iii. Interpretation: Include interpretation of laboratory results, correlating with clinical findings
         iv. Recommended Therapy: Include both transfusion and nontransfusion-based therapies
         v. Discussion: Brief review of literature with unique features of this case
         vi. Reference: Limited to those directly pertinent
         vii. Author information (see II.B.9.)
         viii. Tables (see II.B.7.)

IV. LETTER TO THE EDITOR
A. Preparation
   1. Heading (To the Editor)
   2. Title (first word capitalized)
   3. Text (written in letter [paragraph] format)
   4. Author(s) (type flush right; for first author: name, degree, institution, address [including city, state, Zip code and country]; for other authors: name, degree, institution, city and state)
   5. References (limited to ten)
   6. Table or figure (limited to one)

Send all manuscripts by e-mail to immuno@redcross.org
Subscription Application

United States:  
☐ Institution . . . . $100  
☐ Individual . . . . $50  
☐ Students . . . . $40 (free for 1 year with letter of validation)

Outside United States:  
☐ Institution . . . . $100  
☐ Individual . . . . $60  
☐ Students . . . . $50 (free for 1 year with letter of validation)

NAME ____________________________________________ Degree(s) __________________________

ORGANIZATION __________________________________________________________

DEPT/DIV ________________________________________________________________

STREET _________________________________________________________________

CITY, STATE, ZIP CODE, COUNTRY ____________________________________________

☐ Check if home address used   ☐ Check enclosed*

☐  VISA  

☐  Card Number: ________________ Security Code: ___  Exp. Date: ___ / ___ ___

*Make check payable in U.S. dollars to THE AMERICAN RED CROSS. Mail this card in an envelope addressed to:
Immunohematology, P.O. Box 40325, Philadelphia, PA 19106

THIS FORM MUST ACCOMPANY PAYMENT.

**Billing information may be emailed to: Immuno@redcross.org or via phone to Marge Manigly at 215-451-4902